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1.1 HEART TRANSPLANTATION: A HISTORICAL PERSPECTIVE 
The first human-to-human heart transplant was performed by Christiaan Barnard in South Africa 
on December 3 19671. Pioneering experimental work had been performed by Alexis Carrel, 
Charles Claude Guthrie, Frank Mann, Norman Shumway, and Richard Lower2. Alexis Carrel 
received the 1912 Nobel Prize in Medicine or Physiology for the development of the technique for 
suturing blood vessels3. Seminal experiments in organ transplantation were conducted by Alexis 
Carrel and Charles Claude Guthrie at the University of Chicago in 1904 and 19054-6. Together with 
the aviator Charles Lindbergh, Alexis Carrel invented in the 1930s a mechanical heart that 
circulated vital fluids through excised organs. In the 1930s, Frank Mann and colleagues were able 
to perform heterotopic heart transplantation with puppy hearts with survival of up to eight days7. In 
1958 Keith Reemtsma demonstrated that immunosuppressive agents prolong heart transplant 
survival in the laboratory setting. At the end of the 1950s beginning of the 1960s, Norman 
Shumway and Richard Lower performed revolutionary experimental work in Stanford University on 
developing the technique of orthotopic heart transplantation in dogs. By the mid-1960s, their 
experience led to the conviction that immunologic rejection was the only remaining obstacle to 
successful clinical heart transplantation. However, human heart transplantation was also delayed 
in the USA due to legal restrictions on the use of brain dead donors. 
The first South African heart transplant patient initially recovered well, but died of pneumonia 18 
days later. The second South African heart transplant recipient was the first able to leave the 
hospital and to lead a relatively normal life. He survived for 19 months and died of myocardial 
infarction2.  
The number of heart transplants dropped from 100 in 1968 to only 18 in 1970 because of 
generally poor survival results. Alloimmune responses could not be tackled efficiently. Norman 
Shumway was the only American surgeon to continue performing heart transplantations. Results 
of heart transplantation improved in the second half of the 1970s but the practice was restricted to 
a very limited number of centers. Shumway pioneered the use of cyclosporine, originally isolated 
from the soil fungus Tolypocladium inflatum, in heart transplant recipients. In November 1983, 
cyclosporine was approved for commercial use. The introduction of this drug was pivotal for the 
rise of the heart transplantation field. 
Orthotopic heart transplantation is now a well-established therapy for selected patients with end-
stage congestive heart failure. Whereas this procedure represents one of the most remarkable 
breakthroughs of the past century, a variety of medical problems occur during follow-up of heart 
transplant recipients. Morbidities in heart transplant recipients include acute rejection episodes, 
opportunistic infections, solid and hematological malignancies, renal insufficiency, hypertension, 
osteoporosis, diabetes, and cardiac allograft vasculopathy (CAV). After the first year, CAV and late 
graft failure are the most important cause of death (approximately 30% of mortality) in heart 
transplant recipients followed by malignancy (20%), non-cytomegalovirus (CMV) infection (12%), 
and renal failure (8%)8-11. Severe CAV represents an important indication for re-transplantation. 
CAV can be considered to be a manifestation of chronic rejection. In contrast to liver, lung, and 
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kidney transplants, diagnosis of chronic rejection in cardiac allografts is not based on biopsies but 
on coronary angiography and/or intravascular ultrasound. 
Most of the survival improvement in heart transplant recipients in the past three decades is related 
to mortality reduction during the first post-transplant year10. Mortality beyond 1 year after 
transplant has only slightly declined for patients transplanted in the past 20 years. This lack of 
progress may partially be related to a donor and recipient pool with higher risk characteristics. 
Nevertheless, interventions resulting in a reduction of events leading to long-term mortality are 
needed to achieve further improvements in survival after heart transplant.  
 
1.2 PATHOLOGY OF CARDIAC ALLOGRAFT VASCULOPATHY 
Severe narrowing of epicardial and smaller intramyocardial arteries is the most important 
determinant of cardiac allograft survival and a major cause of death in heart transplant recipients8-
10,12-14. CAV is a generic name for the pathological abnormalities in arteries and veins of 
transplanted hearts. Several alternative terms have been used to describe cardiac allograft 
vasculopathy: transplant coronary artery disease, allograft arteriopathy, cardiac transplant 
arteriosclerosis, transplant atherosclerosis, and transplant vasculopathy. With the exception of 
‘transplant vasculopathy’, all other terms tend to be restrictive or even incorrect. However, these 
various terms partially reflect the heterogeneity of lesions in cardiac allografts14-18. The lesions of 
CAV can be globally categorized into three different entities: atherosclerosis, intimal fibromuscular 
hyperplasia, and vasculitis.  
Atherosclerosis in epicardial arteries is characterized by the presence of atheromata that contain a 
lipid core filled with extracellular cholesterol and cellular debris and are covered by a fibrous cap. 
Inflammation is most often limited to the intima. Atherosclerotic plaques generally occur 
proximally, spare the intramyocardial arteries, and tend to be eccentric.  
In contrast to atherosclerosis, fibromuscular intimal hyperplasia does not contain atheromata, but 
mainly consists of smooth muscle cells and extracellular matrix. Nevertheless, intracellular lipid 
containing foam cells may be present in fibromuscular intimal hyperplasia. Fibromuscular intimal 
hyperplasia is the most prominent lesion of CAV and lesions tend to be circumferential. It not only 
involves the large epicardial arteries but also smaller epicardial arteries and intramyocardial 
arteries. It may also occur in veins. Whereas calcification is an important hallmark of 
atherosclerosis, it is usually not present in fibromuscular intimal hyperplasia.  
Vasculitis is characterized by pronounced inflammation. This inflammation is frequently transmural 
involving intima, media, and adventitia. It occurs in arteries and veins and may be associated with 
destruction of the internal elastic lamina and with necrosis and/or fibrosis of the media. Vasculitis 
occurs in regions of fibromuscular intimal hyperplasia but there appears to be no correlation 
between the degree of inflammation and the proliferative component of the lesion18. Infiltrating 
cells are CD3-positive T lymphocytes and CD68-positive macrophages18. Inflammatory lesions 
may be restricted to ‘endothelitis’ with subendothelial accumulation of inflammatory cells, 
predominantly T cells.  
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The presence of atherosclerosis in allografts has often been attributed to pre-existing lesions in 
the donor. Whereas this may be correct to some degree in adult heart transplant recipients, 
transplant atherosclerosis is also present in pediatric heart transplant recipients with a young 
donor heart18. Therefore, the kinetics of development of atherosclerosis in transplant recipients is 
significantly faster than in native atherosclerosis.  
In conclusion, CAV can be summarized as the triad fibromuscular intimal hyperplasia, 
atherosclerosis, and vasculitis. A further component of vascular pathology in allografts is 
microvasculopathy. In 2007, Hiemann et al.19 concluded that histologically proven stenotic 
microvasculopathy involving the media was a novel prognostic factor for long-term survival. The 
authors conducted a detailed retrospective analysis of more than 9700 endomyocardial biopsies 
obtained during the first year after transplantation from 873 heart transplant recipients. Significant 
epicardial disease (>75% luminal stenosis) was found in 19% of patients at 1 year after 
transplantation, whereas microvascular stenosis was observed in 43% of patients, involving 
predominantly the media (91%) rather than the endothelium. Neither endothelial disease nor 
nonstenotic disease of the media was associated with a worse prognosis. However, stenotic 
microvasculopathy of the media was associated with a significant reduction in overall survival and 
freedom from fatal cardiac events, which was independent of the presence of significant epicardial 
disease. Since this microvasculopathy predominantly involves the media and since atherosclerosis 
and fibromuscular intimal hyperplasia are intimal diseases, it is difficult to envisage that there is a 
close biological link between CAV and microvasculopathy. Furthermore, because of the small size 
of endomyocardial biopsies, the true sensitivity of this technique to detect microvasculopathy is 
unknown unless microvasculopathy is generalized. 
 
1.3 CLINICAL MANIFESTATIONS AND DIAGNOSIS OF CAV  
According to data of the International Society for Heart and Lung transplantation10, the prevalence 
of CAV (defined as any degree of angiographically visible coronary artery disease) is 42% at 7 
years. The prevalence of CAV in UZ Leuven heart transplant recipients is 12%, 25%, 38%, and 
48% at 1 year, 4 years, 7 years, and 10 years after transplantation, respectively (J. Van Cleemput 
and J. Vanhaecke, unpublished results).  
In early and intermediate stages of the disease, CAV is clinically silent. By the time CAV manifests 
as ischemia on functional studies, the disease process is usually well advanced20-23. Often, the 
first symptoms are serious arrhythmias, heart failure, or sudden death. Interventional treatment 
options are limited due to the diffuse nature of the disease, which precludes the routine use of 
percutaneous interventions and coronary artery bypass grafting. Therefore, identification of 
asymptomatic patients at early stages of CAV is critical for the design and implementation of 
strategies for prevention of irreversible detrimental effects of CAV on graft and patient survival.  
Surveillance coronary angiogram is utilized for disease monitoring. Consequently, the end-point is 
a relative change of the lumen diameter compared to a reference segment of the vessel with a 
supposedly normal caliber. Since intimal proliferation in CAV is circumferential and since the 
disease process is diffuse extending into intramyocardial vessels, coronary angiography cannot 
CHAPTER 1 
 
 6 
detect early CAV. In contrast, intravascular ultrasound (IVUS) is a particularly sensitive method to 
detect early CAV and may demonstrate significant intimal thickening in the presence of a normal 
coronary angiogram24. The validity of the increase in maximal intimal thickness quantified by IVUS 
as a surrogate imaging end-point for subsequent angiographic disease and for hard clinical end-
points has been demonstrated24-26. The increase in maximal intimal thickness in any matched slice 
after one year predicts all-cause mortality, death or graft loss or major adverse cardiac events, and 
angiographic CAV24-26. However, serial IVUS measurements in the first year are too cumbersome 
and too expensive for routine clinical use.  
 
1.4 RISK FACTORS FOR CAV 
Donor risk factors for CAV are donor history of hypertension, donor age, donor diabetes, and 
donor tobacco use27. Donor age is a consistent risk factor for CAV in several studies10,25,28,29. 
Recipient risk factors are recurrent acute cellular rejection30, CMV infection10,26,31, dyslipidemia, 
hypertension, pre-existing diabetes, and new-onset diabetes32. The expected correlation between 
the number of human leukocyte antigens (HLA) mismatched between donor and recipient and the 
number or severity of rejection episodes and the development of CAV has not been very 
consistently observed33. Damage to conduit arteries may occur by the large catecholamine surge 
that often accompanies brain death in the donor33. This surge of catecholamines also induces 
contraction band necrosis in the myocardium. The presence of contraction band necrosis on 
endomyocardial biopsies is a risk factor for subsequent development of CAV34. 
In a cross-sectional study, Escobar et al.28 demonstrated that total cholesterol, low density 
lipoprotein cholesterol, triglyceride levels, obesity indices, donor age, and years following cardiac 
transplantation (p<0.01) were independent predictors of the severity of intimal thickening. 
However, statins have become a routine therapy in heart transplant recipients since two trials 
demonstrated the efficacy of pravastatin and simvastatin for the prevention of CAV35,36. The only 
lipid parameter that is quite consistently and independently associated with CAV in the statin era is 
the triglyceride level25,29,37. These observations may be linked with data of a study of Valantine et 
al.38. This report showed that high glucose or insulin plasma concentrations are predictive of 
intimal thickness38. Furthermore, weight indices are also a predictor of CAV25,28,37. Taken together, 
the aggregate information on these metabolic parameters suggests that insulin resistance may 
play a role in the development of CAV38.  
A multivariable analysis of the Registry of the International Society for Heart and Lung 
transplantation10 identified the following risk factors: increasing donor age (p<0.0001), azathioprine 
versus mycophenolate mofetil (RR 1.56; p<0.0001), cyclosporine versus tacrolimus (RR 1.30; 
p<0.0001), and acute rejection prior to discharge (RR 1.30; p<0.0001)10. Tacrolimus and 
mycophenolate mofetil with or without corticosteroids are currently the standard maintenance 
immunosuppressive therapy in most centres.  
Since CAV and late graft loss secondary to CAV are the most important cause of death after the 
first year, the question arises whether the current, quite disparate knowledge on risk factors for 
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CAV is sufficient to take pre-emptive measures and to develop new strategies to counteract CAV. 
The development of risk prediction models will be discussed in paragraph 1.15. 
 
1.5 MAJOR HISTOCOMPATIBILITY ANTIGENS: ROLE IN 
ADAPTIVE IMMUNE RESPONSES 
In humans, major histocompatibility (MHC) antigens are named human leukocyte antigens (HLA). 
Class I HLA molecules (HLA A, B, and C) are expressed on all nucleated cells. They present 
endogenous peptides from within the cell itself and interact with CD8+ T cells. The expression of 
class II HLA molecules (HLA DR, DP, DQ) is restricted to antigen presenting cells (dendritic cells, 
macrophages, B cells) but can also be induced on other cells (e.g. endothelial cells) in the context 
of inflammation. Class II molecules bind peptides that have been derived from the environment 
and engage CD4+ T cells.  
Activation of T cells not only requires recognition of MHC by the T cell receptor (signal 1) but also 
costimulation (signal 2). The best characterised costimulatory molecules are CD28 and CD154 on 
T cells and their corresponding ligands CD80/CD86 (B7-1/B7-2) and CD40, respectively, on 
antigen presenting cells. If T cells receive both signals, an increase of intracellular calcium occurs 
and induces activation of the calcium/calmodulin sensitive molecule, calcineurin. Activated 
calcineurin induces a dephosphorylation of nuclear factor of activated T cells (NF-AT) leading to 
the translocation of this transcription factor to the nucleus. This results in increased transcription 
and translation of interleukin (IL)-2. IL-2 binds to its receptor on the cell surface. The IL-2 receptor 
comprised three subunits. The α subunit of the IL-2 receptor is CD25. Signaling through CD25 
initiates a kinase-dependent cascade that is partially mediated through the mammalian target of 
rapamycin (mTOR). This signaling cascade leads to progression of the cell cycle from G1 to S and 
T cell proliferation ensues.  
 
1.6 IMMUNOSUPPRESSIVE DRUGS IN HEART 
TRANSPLANTATION 
One of the major differences between experimental animal studies investigating allograft 
vasculoapthy and clinical CAV in humans is that human heart transplant recipients are treated with 
immunosuppressive drugs. Besides corticosteroids, three main classes of immunosuppressive 
medications can be discerned: calcineurin inhibitors, purine synthesis inhibitors, and proliferation 
signal inhibitors. 
As described above, transcription of IL-2 is induced following activation of the T cell receptor, 
calcium release, and calcium/calmodulin induced activation of calcineurin. Cyclosporin 
(Cyclosporin A) and tacrolimus (FK506) are calcineurin inhibitors. Cyclosporin binds to the 
cytosolic protein cyclophilin (immunophilin) of T lymphocytes. The complex of cyclosporin and 
cyclophilin inhibits calcineurin. Tacrolimus binds to the 12-kDa immunophilin FK506 binding 
protein (FKBP12). The FKBP12-FK506 complex interacts with and inhibits calcineurin. Important 
side effects of cyclosporin are gingival hyperplasia, hypertension, hypercholesterolemia, and 
nephrotoxicity. Tacrolimus has a less pronounced effect on blood pressure, on serum cholesterol, 
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and on the gingiva. However, diabetes, neurotoxicity, and diarrhea occur more often than in 
patients taking cyclosporin. Results of randomized trials have demonstrated that tacrolimus was 
superior compared to cyclosporin in the prevention of acute rejection episodes39,40. CAV analysed 
by coronary angiography was similar between cyclosporin- and tacrolimus-treated patients in a 
single center randomized trial41. However, follow-up in this trial was limited to 5 years, which may 
be too short for angiographic CAV as an end-point.  
Azathioprine is metabolized into the active 6-mercaptopurine, which is an inhibitor of purine 
synthesis. Suppression of DNA synthesis by 6-mercaptopurine inhibits the proliferation of T cells 
and B cells. Mycophenolate mofetil acts as a reversible inhibitor of inosine monophosphate 
dehydrogenase in purine biosynthesis. Consequently, it inhibits lymphocyte proliferation. Other 
cells are able to recover purines via a separate pathway and are therefore able to escape the 
effect of mycophenolate mofetil. Compared to azathioprine, mycophenolate mofetil is associated 
with less bone marrow suppression and fewer opportunistic infections. A randomized trial 
demonstrated that the combination of mycophenolate mofetil and cyclosporin was associated with 
a 35% reduction in 3-year mortality or graft loss compared to the combination of azathioprine and 
cyclosporin42. Analysis of the development of CAV by intravascular ultrasound showed reduced 
progression in the mycophenolate mofetil group43. In an observational study of Kaczmarek et al.44, 
the rate of freedom from CAV at 5 years was 47% with cyclosporin/azathioprine, 66% with 
cyclosporin/mycophenolate mofetil, 60% with tacrolimus/azathioprine and 70% with 
tacrolimus/mycophenolate mofetil. Multivariate Cox regression analysis revealed that 
mycophenolate mofetil was associated with a lower incidence of CAV (p = 0.041)44. 
Sirolimus, also known as rapamycin, belongs to the proliferation signal inhibitors. It binds to the 
immunophilin FKBP12 similar as tacrolimus. In contrast to the tacrolimus-FKBP12 complex, the 
sirolimus-FKBP12 complex does not inhibit calcineurin but binds mTOR Complex 1 (mTORC1). 
Consequently, IL-2 signaling is suppressed. Everolimus is a derivative of sirolimus and is also an 
mTOR inhibitor. Important side-effects of everolimus are impaired wound healing, significant 
nephrotoxicity when used in combination with standard doses of calcineurin inhibitors, and mouth 
ulcers45. In a randomized clinical trial comparing everolimus and azathioprine, everolimus 
significantly reduced the proportion of patients reaching at 6 months the primary efficacy end-point 
composed of death, graft loss or re-transplantation, loss to follow-up, biopsy-proved acute 
rejection of grade 3A, or rejection with hemodynamic compromise46. Everolimus was more 
efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft 
vasculopathy at 12 months46. In a randomized trial comparing everolimus plus reduced dose 
calcineurin inhibition versus standard dose calcineurin inhibition, CAV progression was attenuated 
with everolimus versus standard calcineurin inhibition when patients on azathioprine therapy were 
considered47. However, in patients receiving mycophenolate mofetil, accelerated CAV progression 
occurred with everolimus versus standard calcineurin inhibition. Beneficial effects of sirolimus on 
progression of CAV have also been demonstrated48,49.  
An important caveat is that trials on the effect of mycophenolate mofetil and of mammalian target 
of rapamycin inhibitors inhibitors were conducted on a background of cyclosporine and steroids 
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and comparison of the drug of interest (mycophenolate mofetil, everolimus, sirolimus) was made 
with azathioprine. Standard maintenance immunosuppressive therapy in most centres consists at 
present of the calcineurin inhibitor tacrolimus combined with mycophenolate mofetil with or without 
steroids. This implies that the question whether mammalian target of rapamycin inhibitors 
(everolimus, sirolimus) are superior compared to mycophenolate mofetil in prevention of CAV 
cannot be answered. 
1.7 ALLOIMMUNE RESPONSES AND MHC RESTRICTION: A 
CHALLENGING PARADOX IN CELLULAR IMMUNITY 
Incompatibility between donor cells and recipient cells is the main threat for the long-term success 
of solid organ transplantation. Allorecognition involves the detection of non-self antigens by the 
host immune system50. The recognition of self versus non-self occurs via MHC. The number of 
HLA polymorphism in humans is very high. There is possibility for variation in all twelve classic 
HLA alleles. Intact MHC molecules are a major target in allorecognition. There are also minor 
histocompatibility antigens e.g. the Y-linked minor histocompatibility antigens (H-Y antigen)51. 
T cell alloreactivity, involving recognition of allogeneic MHC molecules by MHC-restricted T cells, 
is a challenging paradox in cellular immunity52. The primary function of MHC molecules is to 
initiate an immune response by presenting antigenic peptides on the cell surface for recognition by 
the T cell receptor52. As demonstrated by Zinkernagel and Doherty in 1974, this interaction is 
restricted: it occurs only between T cells and antigen presenting cells originating from a syngeneic 
background53. In humans, MHC restriction basically implies that T lymphocytes can only detect an 
antigen if this antigen is displayed by an MHC molecule from the same individual. MHC restriction 
is the result of positive selection in the thymus: immature thymocytes that initially express both the 
CD4 and CD8 co-receptors undergo apoptosis if they do not receive a positive survival signal 
through their T cell receptor by interaction with thymic epithelial cells that present self-peptides 
bound to MHC. Positive selection by weak interaction with these self-peptide:MHC complexes 
leads to further maturation into single positive CD4+ or CD8+ lymphocytes54. Immature thymocytes 
that react too strongly with self-peptide:MHC complexes undergo clonal deletion by apoptosis. 
This is negative selection55. As a result of positive and negative selection, mature lymphocytes 
exhibit specificity for self-MHC:foreign antigen complexes and lack autoreactive properties. 
MHC restriction of T lymphocytes is the logical consequence of positive and negative selection in 
the thymus. The critical role of the displaying MHC molecules in antigen presentation reflects that 
the T cell receptor recognizes some residues of an antigenic peptide together with some residues 
from the displaying MHC molecule. Based on the principle of MHC restriction, it seems 
contradictory that T cells may react against a foreign peptide:foreign MHC complex. This appears 
to be due to the fact the MHC molecule of the donor is similar to self-MHC molecule in the binding 
region to the T cell receptor. Consequently, the foreign peptide:foreign MHC complex is 
recognized as an apparent foreign peptide:self-MHC complex.  
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1.8 ALLOIMMUNE RESPONSES: THE DIRECT AND THE 
INDIRECT PATHWAY 
There are two pathways of T cell activation in alloimmunity. The direct pathway is unique to 
transplantation. Recipient CD4+ and CD8+ T cells recognize and respond to donor peptide:donor 
HLA complexes on graft-derived cells. Specifically, CD8+ T cells directly engage endogenous 
donor peptide:HLA class I complexes on donor APCs, receive costimulatory signals, and become 
activated. CD4+ T cells may be directly activated by donor peptide:MHC class II complexes on 
donor APCs. Since T cell activation requires costimulatory signals, the direct pathway will be 
highly dependent on bone marrow-derived, specialized APCs from the donor. Once the donor 
APCs have been depleted from the donor heart, as occurs within weeks of transplantation, the 
parenchymal and resident cells of the donor heart are incapable of driving direct pathway 
activation of recipient T cells. On the contrary, direct allorecognition in the absence of 
costimulation may have a tolerizing effect56. However, donor endothelial cells may also play a role 
in direct alloantigen presentation (cfr. infra). 
Indirect allorecognition occurs when donor histocompatibility molecules are internalized, 
processed, and presented as peptides by recipient antigen presenting cells. Thus, the 
fundamental difference between the direct and indirect pathway is that in the former the antigen 
presenting cell is of donor origin. In the indirect pathway, host T cells recognize graft alloantigens 
presented by a host APC. This form of antigen presentation by the MHC class II molecule targets 
class II-restricted host CD4+ T cells, resulting in their activation in response to the graft. The direct 
pathway likely plays a dominant role in acute rejection. The indirect pathway is likely to be 
permanently active since recipient APCs migrate through the graft and may pick up donor 
antigens. The indirect pathway plays a role in acute rejection episodes and in chronic rejection. 
Chronic rejection is the likely key player of the development of CAV. Chronic rejection also occurs 
in kidney allografts, lung allografts, and liver allografts and the corresponding pathologies are 
named chronic allograft nephropathy, bronchiolitis obliterans and vanishing bile-duct syndrome. 
 
1.9 THE ROLE OF THE ENDOTHELIUM IN ALLOIMMUNITY 
Endothelial cells of coronary arteries are the first biological interface between the donor allograft 
and circulating immunocompetent cells of the heart transplant recipient. The endothelium is 
activated in allografts. This implies expression of adhesion molecules (e.g., E-selectin, intercellular 
adhesion molecule-1), secretion of cytokines and chemokines, and also expression of molecules 
that provide costimulatory signals for lymphocyte activation. Importantly, activated CD4+ T cells 
stimulate the expression of HLA class-II molecules on endothelial cells. 
Whereas the endothelium may be a target of alloimmune responses, donor endothelial cells may 
initiate allospecific immune responses by expressing MHC class II antigens with subsequent direct 
activation of CD4+ T cells57. It has been shown that direct CD8+ T cell activation by endothelial 
cells can trigger acute cardiac allograft rejection58. Taken together, human graft endothelial cells of 
donor origin may activate allogeneic host T cells through direct presentation of MHC molecules in 
GENERAL INTRODUCTION 
 
 11 
the presence of sufficient costimulation59. On the other hand, it has been suggested that graft 
endothelium replacement by recipient-type cells is required for the rejection of cardiac allografts 
mediated by indirect pathway alloreactive CD4+ T cells60. In any case, it is uncertain whether 
replacement of donor endothelium by recipient endothelial cells is beneficial. As long as the 
endothelium is activated, recipient dendritic cell invasion is increased61. These dendritic cells may 
pick up donor alloantigens, migrate to secondary lymphoid organs, and activate CD4+ T cells via 
the indirect pathway. 
 
1.10 THE ROLE OF THE ENDOTHELIUM IN THE PATHOGENESIS 
OF CAV 
The endothelium regulates vascular tone, inflammation, smooth muscle cell proliferation, and 
thrombosis62. In the ‘response to injury’ concept of CAV, vascular lesions are considered to be the 
result of cumulative endothelial injury both by alloimmune responses and by non-alloimmune 
insults63 (Figure 1.1). T cell alloimmunity, antibody-mediated immune attack, and non-immune 
factors induce endothelial cell death or endothelial dysfunction. Cellular infiltrates in the vessel wall 
of heart transplant recipients with CAV are predominantly T cells that are mainly localized in the 
neointima and the adventitia64. Endothelitis associated with subendothelial accumulation of T 
lymphocytes is a manifestation of chronic rejection. Endothelial injury initiates an inflammatory 
cascade, which is associated with the activation of macrophages and proliferation of smooth 
muscle cells. Recruitment of monocytes is dependent on chemokines and cytokines produced by 
T cells and endothelial cells. Concentric intimal thickening is the outcome of smooth muscle cell 
migration and proliferation as a result of the dysfunctional endothelium and cytokines produced by 
monocytes. The process of endothelial injury is counteracted by endothelial repair mechanisms 
that will be discussed in detail below.  
Endothelial injury likely plays a central role in the pathogenesis of CAV. However, the scheme of 
the pathogenesis of CAV described above is highly conceptual and does not make a distinction 
between true causes (conditio sine qua non) and modifiers. Since CAV is only observed in 
transplant patients and specifically in allografts and not in isografts, alloimmunity plays an 
overwhelming and causative role in the development of CAV. CAV has long been referred to as 
chronic rejection8. Non-alloimmune factors are modifiers of the pathology. Endothelial injury is a 
mediator. It is an intermediate variable between cause or modifiers and the pathological 
manifestations. 
One should also keep in mind that CAV is not a uniform pathological process. Although 
fibromuscular intimal hyperplasia is the dominant pathological manifestation, transplant 
atherosclerosis in large epicardial arteries is also observed. Different pathological manifestations 
indicate different pathogenetic mechanisms. 
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Figure 1.1. Schematic representation of the role of endothelial injury and endothelial repair 
in the development of cardiac allograft vasculopathy (CAV). Alloimmune endothelial injury 
likely plays a causal role in the development of CAV. Non-alloimmune factors may modify 
endothelial injury. Endothelial dysfunction and injury may initiate a cascade of events 
including platelet activation and inflammation with infiltration of predominantly 
macrophages and T cells in the intima and the adventitia. Endothelial dysfunction and 
injury and subsequent vessel wall inflammation induce smooth muscle cell activation, 
migration, and proliferation. Activation and injury of endothelial cells may also cause the 
shedding off of endothelial cells in peripheral blood as viable circulating endothelial cells 
(CECs) or as apoptotic CECs. Endothelial microparticles are also present in the peripheral 
blood but the exact mechanism and origin of their formation is not known. Bone marrow 
derived progenitor cells contribute to restoration of vascular endothelial integrity via 
paracrine effects or via incorporation into the endothelium . Progenitor cells include early 
endothelial progenitor cells (EPCs), endothelial colony forming cells (ECFCs), and 
hematopoietic progenitor cells (HPCs). Early EPCs and HPCs release pro-angiogenic 
factors whereas ECFCs directly contribute to reendothelialization. 
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1.11 ENDOTHELIAL REPAIR MECHANISMS  
Endothelial progenitor cells (EPCs) play a role in maintaining the integrity of the vascular 
endothelium (Figure 1.1). In the literally correct sense of the word, EPCs are immature precursor 
cells capable of differentiating into mature endothelial cells in vivo. However, the term endothelial 
progenitor cell (EPC) is used in a very broad sense in the literature. EPCs encompass different 
categories of cells with different phenotypic and functional properties that affect neovascularization 
and reendothelialization. Different protocols for short-term culture of blood mononuclear cells on 
fibronectin (with or without gelatin)-coated plates have been established by Vasa et al.65 and Hill et 
al.66. These cells are stimulated by culture conditions to mimic many features of endothelial cells67. 
However, the putative EPCs identified by these assays do not give rise to a lineage of endothelial 
progeny, but cultured cells consist of monocytes or a population of hematopoietic cells with 
monocyte-macrophage or T cell lineage commitment. The cells identified in these assays may 
regulate the angiogenic response in a paracrine way68 by releasing angiogenic factors that 
promote reendothelialisation indirectly. These cells have been called circulating angiogenic cells or 
pro-angiogenic progenitor cells67. Nevertheless, EPCs defined in the literally correct sense of the 
word do exist. Using high-power laser multichannel scanning confocal microscopy to visualize 
three-dimensional vascular structures, incorporating bone marrow-derived EPCs have been 
unambiguously identified in allografts69. Incorporation of EPCs has also been observed in a murine 
model of vein graft atherosclerosis70. In vitro, endothelial colony forming cells (ECFCs) or blood 
outgrowth endothelial cells (BOECs) are derived from long-term culture of adherent peripheral 
blood mononuclear cells in endothelial conditions and consist of colonies that display a 
cobblestone morphology70,71. ECFCs express cell surface antigens like primary endothelium, 
clonally propagate, can be replated into secondary and tertiary ECFCs, form capillary-like 
structures in vitro, and become endothelial cells in vivo71. The term EPC is used in this doctoral 
thesis in the broad sense of the word. Taken together, increased EPC number and function may 
enhance endothelial repair in allografts, directly via increased EPC incorporation (‘building block’ 
role) or indirectly via production of growth factors (paracrine role).  
As discussed supra, cells that were originally identified as EPCs are in fact hematopoietic lineage 
cells. Cells of the hematopoietic lineage may be mobilized from the bone marrow and are 
entrapped in peripheral tissues, where they release angiogenic signals. Common myeloid 
progenitors and granulocyte-macrophage progenitors may differentiate into pro-angiogenic cells72 
and may promote neovascularization and endothelial repair. A comprehensive analysis of 
endothelial repair mechanisms should therefore not be restricted to EPC quantifications but also 
entail quantifications of hematopoietic progenitor cells. 
1.12 ENDOTHELIAL CELL DEATH AND TURNOVER  
In healthy individuals, the endothelial layer is renewed at a low replication rate of 0-1% per day73. 
The measurement of immunologically-defined circulating endothelial cells (CECs) is a direct 
method to assess vascular integrity74. Endothelial cells can be activated by various stimuli such as 
CHAPTER 1 
 
 14 
cytokines, growth factors, infectious agents, lipoproteins, or oxidative stress. In allografts, 
antibody-mediated rejection or cellular rejection may induce endothelial cell activation. Prolonged 
activation may lead to loss of integrity of the endothelial layer and cell detachment. Detached cells 
may be viable, apoptotic, or necrotic75. Apoptotic CECs can be quantified by including Annexin V 
staining in the protocol. It has been shown that cells undergoing apoptosis break up the 
phospholipid asymmetry of their plasma membrane and expose phosphatidylserine, which is 
translocated to the outer layer of the membrane76. Annexin V preferentially binds to negatively 
charged phospholipids like phosphatidylserine in the presence of Ca2+ and shows minimal binding 
to phosphatidylcholine and sphingomyeline. Quantification of CECs and apoptotic CECs 
represents a sensitive and specific marker of endothelial damage. In contrast, soluble markers like 
von Willebrand factor, thrombomodulin, and E-selectin do not distinguish between endothelial cell 
activation and endothelial damage, and are therefore not suitable to measure endothelial turnover.  
Apoptotic circulating endothelial microparticles (CEMPs) constitute another parameter to measure 
endothelial damage. They result from exocytic budding following endothelial cell activation and 
consist of phospholipids surrounding a cytoplasmic component77. Apoptotic CEMPs can be 
quantified by flow cytometry based on size, presence of an endothelial surface marker, and 
Annexin V staining.  
 
1.13 RELATION BETWEEN EPCS AND CAV 
In a small study comparing 8 patients with CAV and 7 patients without CAV, Simper and 
colleagues78 observed that the number of EPC colony-forming units (late outgrowth EPCs) 
appearing over a 6-week culture period was significantly lower in patients with CAV. In contrast, 
no significant difference in early EPC number was observed after 4 days of culture. The authors 
analyzed the origin of endothelial cells in the graft in sex-mismatched cardiac transplantation 
recipients based on fluorescent in situ hybridization for the Y chromosome and immunostaining for 
CD31. The percentage of recipient-derived luminal endothelial cells ranged from 1% to 24% in 
diseased segments but was significantly lower than 1% in non-diseased segments. 
Thomas et al.79 compared 17 patients with CAV and 17 patients without CAV. No difference in the 
number of CD34+, CD34+CD45+, CD133+, CD34+CD133+, CD34+VEGFR-2+, CD133+VEGFR-2+, 
and CD34+CD133+ VEGFR-2+ cells was observed between both groups. The fact that 7 different 
categories were quantified indicates that a unique immunophenotypic definition of EPCs does not 
exist. More recently, Schober et al.80 compared 84 patients with CAV and 103 patients without 
CAV. The number of CD34+VEGFR-2+ cells was not significantly different in patients with CAV and 
without CAV. Taken together, most evidence indicates that there is no relation between the 
number of EPCs and the presence of CAV. However, definitions of EPCs based on 
immunophenotype may not be adequate. In addition, no information on EPC function in heart 
transplant recipients is available. 
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1.14 THE ORIGIN OF THE ENDOTHELIUM IN ALLOGRAFTS 
The origin of the endothelium in allografts remains relatively unclear. As discussed supra, the data 
of Simper et al.78 suggest that recipient-derived luminal endothelial cells constitute a minority or a 
small minority of the endothelium in allografts. Whereas these data are based on sex-mismatch, 
information may also be obtained in the case of ABO-compatible, non-identical cardiac 
transplantation (A receiving heart from O, B receiving heart from O, AB receiving from heart A, B, 
or O). O’Connell et al.81 found that the endothelial cells in the graft expressed characteristics of the 
recipient in 30% of recipients in the first year after transplantation. In half of these hearts, reversal 
of the phenotype was partial, in the other half it was complete. 
Koestner et al.82 reported the results on an ABO mismatched heart transplantation: a 19-year old 
patient with blood group type O accidentally received a blood group B cardiac allograft. This 
patient had an Ivemark syndrome (congenital univentricular heart, situs inversus, and asplenia). 
The patient died 5 years after transplantation because of cardiac allograft vasculopathy. The 
antigenic profile of the graft endothelial cells progressively changed between 15 and 30 months 
from B to O. By 44 months post-transplantation, it had changed to the O type (H antigen on 
endothelial cells). In ABO-mismatched heart transplants in infants, no change in the antigenic 
profile of the graft endothelium was observed83.  
 
1.15 RISK PREDICTION MODELS FOR CAV  
Risk prediction models are well-established for native coronary artery disease. Examples of 
prognostic prediction models for coronary heart disease are The Framingham risk score84 and 
Systemic Coronary Risk Estimation (SCORE)85. At present, there are no well-established and 
robust prediction models for prevalent or incident CAV.  
A diagnostic prediction model was developed by Mehra et al. in 199529. In this study, a score 
based on donor age higher than 35 years, a first year mean biopsy score higher than 1, and 
hypertriglyceridemia at two levels of risk (150-250 mg/dl or higher than 250 mg/dl) predicted the 
probability for severe intimal hyperplasia in 101 subjects29. This model was subsequently validated 
in 37 patients. Substantial changes in heart transplantation have occurred since 1995 in particular 
improved immunosuppressive therapy and altered recipient and donor characteristics. The 
proportion of patients being bridged to transplant with mechanical circulatory support continues to 
increase rapidly with 36% of patients being on mechanical support at the time of transplant in 
201010. The median donor age has steadily increased and is now for instance more than 40 years 
in Europe10. 
Instead of using biochemical markers or clinical data to predict the presence or the incidence of 
CAV, serial first-year IVUS data have been used as a surrogate imaging end-point to predict 
angiographic CAV and/or clinical outcomes24-26. In 1999, Kapadia et al.24 were the first to report 
the impact of rapidly progressive intimal thickening (>0.5 mm increase in intimal thickening from 
baseline in the first year of transplantation) in 100 transplant recipients. Patients with first-year 
rapidly progressive intimal thickening had more subsequent events (death, myocardial infarction, 
CHAPTER 1 
 
 16 
and heart failure) compared with patients without rapidly progressive intimal thickening (25% 
versus 11%) during a follow-up period of 43 months. The most solid evidence for serial first-year 
IVUS data as a surrogate marker to predict angiographic CAV and poor outcomes after heart 
transplantation comes from two publications in 200525,26. Kobashigawa et al.25 demonstrated that 
progression of maximal intimal thickening ≥ 0.5 mm in the first year after transplant predicted 
death or graft loss (20.8% versus 5.9%; p=0.007), the composite end-point of death or graft loss or 
nonfatal major adverse cardiac events (45.8% versus 16.8%; p=0.003), and had more findings of 
newly occurring angiographic luminal irregularities (75.2% versus 32.6%; p=0.0004) during a five-
year follow-up period. Tuzcu et al.26 defined rapidly progressive vasculopathy as an increase of 
maximal intimal thickness ≥ 0.5 mm in the first year after transplant. After a median follow-up of 
5.9 years, more patients with rapidly progressive vasculopathy died as compared to those without 
(26% versus 11%, p=0.03). The composite end-point of death and myocardial infarction also 
occurred more frequently among those with rapid progression than in those without it (51% versus 
16%, p<0.0001). The IVUS-defined rapid progression predicted future development of 
angiographic CAV. Donor transmitted lesions were not predictive of outcome. Serial first-year 
IVUS cannot be applied in routine clinical practice. 
Based on the existing literature (cfr. paragraph 1.4), it becomes clear that traditional risk factor 
approaches are markedly insufficient as a foundation for risk prediction models. Biomarkers that 
capture key processes or key players in the pathogenesis of CAV may be the cornerstone of 
adequate prediction models. These cardiovascular biomarkers should not simply be evaluated in 
isolation for their predictive abilities but on their added predictive contribution beyond existing or 
established predictors86. 
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Cardiac allograft vasculopathy (CAV) is a limiting factor for the long-term survival of heart 
transplant recipients1,2. CAV is characterized by the development of diffuse concentric 
fibromuscular intimal hyperplasia lesions in epicardial and smaller intramyocardial arteries along 
with focal, eccentric atherosclerotic plaques in the larger epicardial arteries3,4. The development of 
these lesions may lead to the progressive narrowing of the lumen5. According to the response to 
injury hypothesis of CAV, these lesions are the result of cumulative endothelial injury induced by 
alloimmune responses as well as non-immunological risk factors such as ischemia-reperfusion 
injury, viral infections, and metabolic disorders3,6.  
Early diagnosis of CAV is essential to implement appropriate prevention and treatment measures. 
Clinical prediction models of CAV are currently not available and may be useful for non-invasive 
diagnostic and prognostic purposes. The general aim of this doctoral thesis is to develop 
diagnostic prediction models for prevalent CAV. The central hypothesis of my PhD studies is that 
biomarkers of endothelial homeostasis discriminate between CAV negative and CAV positive 
heart transplant recipients. The validity of this hypothesis will be specifically demonstrated in 
chapter 3.1 and chapter 3.4.  
 
The precise aims of the four chapters comprised in this doctoral thesis can be summarized as 
follows: 
 
1. The hypothesis evaluated in chapter 3.1 was that biomarkers of endothelial homeostasis would 
constitute a solid foundation for the development of clinical prediction models of CAV. Therefore, 
the objective of the first study was to evaluate whether biomarkers related to endothelial repair 
(endothelial progenitor cell (EPC) number, EPC function, hematopoietic progenitor cell (HPC) 
number) and to endothelial injury ((apoptotic) circulating endothelial cells (CECs), (apoptotic) 
circulating endothelial microparticles (CEMPs)) discriminate between CAV negative and CAV 
positive heart transplant recipients. In this cross-sectional study, 22 CAV negative patients and 30 
positive patients between 5 and 15 years after heart transplantation were included. 
 
2. The aim of the second cross-sectional study was to compare CECs, CEMPs, and platelet 
microparticles (PMPs) between heart transplant recipients and patients with stable native coronary 
artery disease (CAD). After all, according to the response to injury hypothesis of Russell Ross7,8, 
endothelial dysfunction/injury induced by various insults is the trigger for atherosclerosis 
development. To perform this study, 80 patients undergoing coronary angiography for stable 
native CAD were recruited. Since CAV and native CAD are two entirely distinct categories, the 
main objective of this study was to test the hypothesis that biomarkers of endothelial injury 
(endothelial activation or endothelial damage) are distinct in patients with native CAD and heart 
transplant recipients with CAV. 
 
3. The relation between high density lipoprotein (HDL) cholesterol levels and CAV is controversial 
in the literature. In this cross-sectional study, the hypothesis that HDL is dysfunctional in heart 
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transplant recipients was investigated. Heart transplant recipients were compared with a healthy 
control reference group. Moreover, the objective of this study was to evaluate whether HDL 
function assays may discriminate between CAV negative and CAV positive heart transplant 
recipients. To assess cholesterol efflux capacity of HDL, we used a validated assay that was 
designed to integrate the efflux pathways thought to be operative in vivo9. Cholesterol efflux 
capacity analyzed by this assay was a stronger predictor of prevalent atherosclerotic burden than 
HDL cholesterol or apolipoprotein (apo) A-I in the study by Khera et al.9. Since cumulative 
endothelial injury induced by both alloimmune responses and non-alloimmune insults is thought to 
be central in the pathogenesis of CAV2,10, we also assessed the vasculoprotective function of HDL 
by use of an EPC migration assay11,12.  
 
4. The aim of chapter 3.4 was to analyze the potential of endothelium-enriched microRNAs 
(miRNAs) as putative biomarkers for the prediction of CAV. MiRNAs are small, non-coding, single-
stranded RNA sequences that regulate gene expression at the post-transcriptional level. Because 
miRNAs circulate in remarkably stable forms in blood13,14, they have a significant potential as 
biomarkers. Several reports indicate that miRNAs may play a role in endothelial homeostasis15,16. 
In this study, a candidate-based approach using circulating levels of endothelium-enriched 
miRNAs (miR-21-5p, miR-92a-3p, miR-92a-1-5p, miR-126-3p, miR-126-5p) to predict CAV was 
investigated. 
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Chapter 3 
 
 
3 Experimental studies 
 
 
 

  
3.1 CIRCULATING APOPTOTIC ENDOTHELIAL CELLS AND 
APOPTOTIC ENDOTHELIAL MICROPARTICLES 
INDEPENDENTLY PREDICT THE PRESENCE OF CARDIAC 
ALLOGRAFT VASCULOPATHY*
3.1.1 ABSTRACT 
 
 
Objectives: Maintenance of endothelial homeostasis may prevent the development of cardiac 
allograft vasculopathy (CAV). This study investigated whether biomarkers related to endothelial 
injury and endothelial repair discriminate between CAV-negative and CAV-positive heart 
transplant recipients. 
Background: CAV is the most important determinant of cardiac allograft survival and a major 
cause of death after heart transplantation. 
Methods: Fifty-two patients undergoing coronary angiography between 5 and 15 years after heart 
transplantation were recruited in this study. Flow cytometry was applied to quantify endothelial 
progenitor cells (EPCs), circulating endothelial cells (CECs), and endothelial microparticles. Cell 
culture was used for quantification of circulating EPC number and hematopoietic progenitor cell 
(HPC) number and for analysis of EPC function. 
Results: The EPC number and function did not differ between CAV-negative and CAV-positive 
patients. In univariable models, age, creatinine, steroid dose, granulocyte colony-forming units, 
apoptotic CECs, and apoptotic endothelial microparticles discriminated between CAV-positive and 
CAV-negative patients. The logistic regression model containing apoptotic CECs and apoptotic 
endothelial microparticles as independent predictors provided high discrimination between CAV-
positive and CAV-negative patients (C-statistic 0.812; 95% confidence interval: 0.692 to 0.932). In 
a logistic regression model with age and creatinine as covariates, apoptotic CECs (p=0.0112) and 
apoptotic endothelial microparticles (p=0.0141) were independent predictors (C-statistic 0.855; 
95% confidence interval: 0.756 to 0.953). These two biomarkers remained independent predictors 
when steroid dose was introduced in the model. 
Conclusions: The high discriminative ability of apoptotic CECs and apoptotic endothelial 
microparticles is a solid foundation for the development of clinical prediction models of CAV. 
                                                 
* This chapter has been published as: Singh, N., Van Craeyveld, E., Tjwa, M., Ciarka, A., 
Emmerechts, J., Droogne, W., Gordts, S., Carlier, V., Jacobs, F., Fieuws, S., Vanhaecke, J., Van 
Cleemput, J., De Geest, B. Circulating apoptotic endothelial cells and apoptotic endothelial 
microparticles independently predict the presence of cardiac allograft vasculopathy. Journal of the 
American College of Cardiology 2012; 60 (4), 324-331 
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3.1.2  INTRODUCTION 
Cardiac allograft vasculopathy (CAV) in heart transplant recipients is characterised by the 
coexistence of diffuse fibromuscular intimal hyperplasia and focal atherosclerosis1,2. It is largely an 
immunological phenomenon that is modified by non-immunological factors. Diffuse concentric 
lesions of fibromuscular intimal hyperplasia develop in the epicardial and the smaller 
intramyocardial arteries whereas focal, eccentric atherosclerotic plaques are observed in the 
larger epicardial arteries1,2. CAV may lead to late graft failure and is, in addition to malignancy, the 
most important cause of death in heart transplant recipients after the first year1,3,4.  
According to the response to injury concept of CAV, vascular lesions are considered to be the 
result of cumulative endothelial injury by both alloimmune responses and non-alloimmune 
insults1,5. T-cell alloimmunity, antibody-mediated immune attack, and non-immune factors induce 
endothelial activation or endothelial cell death. This may initiate a cascade of events including 
platelet activation and inflammation with infiltration of predominantly macrophages and T cells in 
the vessel wall followed by smooth muscle cell activation, migration, and proliferation.  
To maintain endothelial homeostasis, endothelial cell death should be balanced by endothelial 
repair mechanisms. After endothelial cell detachment induced by prolonged activation of 
endothelial cells or immunological injury, endothelial cells can be detected in the peripheral blood 
as viable circulating endothelial cells (CECs) or as apoptotic CECs6,7. In addition to CECs, 
endothelial microparticles constitute another biomarker of endothelial injury. Endothelial 
microparticles arise from exocytic budding after endothelial cell activation or apoptosis8-10. The 
process of endothelial injury is counteracted by endothelial repair mechanisms. Increased 
endothelial progenitor cell (EPC) number and function may enhance endothelial repair in 
allografts, directly via increased EPC incorporation (‘building block” role) or indirectly via 
production of growth factors (paracrine role). EPCs that promote re-endothelialization in a 
paracrine way have been named pro-angiogenic progenitor cells11 and are in fact hematopoietic 
lineage cells. Cells of the hematopoietic lineage may be mobilized from the bone marrow and are 
entrapped in peripheral tissues, where they release angiogenic signals12. A comprehensive 
analysis of endothelial repair mechanisms should therefore not be restricted to classical EPC 
quantifications but also entail enumeration of hematopoietic progenitor cells (HPCs). 
Clinical prediction models of CAV are currently not available and may be useful for noninvasive 
diagnostic and prognostic purposes. Our hypothesis was that biomarkers of endothelial 
homeostasis would constitute a solid foundation for the development of such clinical prediction 
models. Therefore, the objective of the current study was to evaluate whether biomarkers related 
to endothelial repair (EPC number, EPC function, HPC number) and to endothelial injury 
((apoptotic) CECs, (apoptotic) endothelial microparticles)) discriminate between CAV-negative and 
CAV-positive heart transplant recipients.  
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3.1.3 METHODS 
3.1.3.1 Patient population and CAV grading 
 
Fifty-two patients undergoing coronary angiography in the framework of their routine follow-up 
between 5 and 15 years after heart transplantation were recruited in this cross-sectional study. 
Heart transplant recipients with prior congenital heart disease and patients who underwent 
retransplantation were excluded.  The study was approved by the Ethics Committee of the 
University Hospital Gasthuisberg and written informed consent was obtained from all participating 
subjects. To establish reference values of selected biomarkers, 25 healthy control subjects age 
43.2 ± 2.0 years were selected. 
Coronary angiograms were analyzed by three transplant cardiologists (A.C., W.D., and 
J.V.C.). CAV was graded according to the International Society for Heart and Lung 
Transplantation working formulation of a standardized nomenclature for CAV-201013. Patients 
with CAV1, CAV2, and CAV3 were pooled and constitute the CAV-positive group. Patients with 
CAV0, defined as no detectable angiographic lesion, constitute the CAV-negative group.  
Endomyocardial biopsies were scored for acute rejection according to Billingham et al.14 and 
mean biopsy score of all biopsies in the first year was calculated according to Mehra et al.15. 
 
3.1.3.2 Quantification of EPC number and EPC function based on cell culture assays 
 
Peripheral blood was anticoagulated with sodium heparin and mononuclear cells were isolated 
from 18 ml of blood by density gradient centrifugation with Ficoll-PaqueTM PLUS (Stem Cell 
Technologies, Grenoble, France), according to the manufacturer’s protocol. Mononuclear cell 
count was determined using a Nucleocounter (Chemometec, Allerød, Denmark). 
Cultivation of early EPCs was performed as described by Vasa et al.16. Briefly, mononuclear 
cells were plated onto fibronectin-coated 24-well culture dishes (BD Biosciences, San Jose, 
CA, USA) in endothelial basal medium (EBM; Cambrex, East Rutherford, NJ, USA) 
supplemented with endothelial growth medium SingleQuots (Cambrex) and 20% fetal bovine 
serum (Invitrogen, Carlsbad, CA, USA) at a density of 4 x 106 cells/well. After 4 days of incubation, 
EPCs were quantified as the number of 1,1’-dioctadecyl-3,3,3’,3’- tetramethylindocarbocyanine-
labeled acetylated LDL (DiI-acLDL) FITC-labeled Ulex europaeus agglutinin- I ( U E A - I )  lectin 
double positive cells, per microscopy field. Experiments were performed in duplicate. 
Migration of cultured early EPCs was studied as previously described16,17. Stromal derived 
factor-1α ( S D F - 1α) (100 ng/ml; R&D Systems, Inc., Minneapolis, MN, USA) was added in the 
lower chamber. 
 
3.1.3.3 HPC culture assay  
 
Cultivation of HPCs was performed using semisolid methylcellulose-based medium (Methocult
® 
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H4434 Classic; Stem Cell Technologies), according to the manufacturer’s protocol. Briefly, 
peripheral blood mononuclear cells (1 x 105 cells/dish and 2 x 105 cells/dish) were seeded in 35-
mm culture dishes (Stem Cell Technologies) in 2 ml of Methocult medium (Stem Cell 
Technologies). After 14 days of incubation, erythroid burst-forming units, erythroid colony-forming 
units, granulocyte colony-forming units, macrophage colony-forming units, granulocyte, 
macrophage colony-forming units; and granulocyte, erythrocyte, macrophage, megakaryocyte 
colony-forming units were enumerated using an inverted microscope.  
3.1.3.4 Quantification of the number of circulating EPCs, endothelial cells, and 
endothelial microparticles by flow cytometry 
 
EPC concentration was also measured by fluorescence activated cell sorting analysis of the 
circulating number of CD34 vascular endothelial growth factor receptor (VEGFR)-2 double 
positive cells, as described previously18,19. 
CECs were identified as CD45- CD31bright VEGFR-2+ mononuclear cells20. Annexin V staining 
distinguishes between viable and apoptotic CECs21. Samples were acquired on a high flow rate 
(120 µl/min) for 3 min using a BD FACSCantoII flow cytometer and BD FACSDIVA software 
version 1.2.6 (BD Biosciences), with a minimum detection number of 100,000 events within the 
mononuclear cell gate. 
Blood that was used for microparticle quantification by flow cytometry was anticoagulated with 
sodium citrate. To exclude microparticles derived from nonendothelial cells, mainly platelets, 
endothelial microparticles were defined as CD144 (VE-Cadherin)+ CD42a- microparticles22. 
Annexin V binding was used to discriminate between apoptotic and nonapoptotic microparticles. 
Apoptotic endothelial microparticles were defined as Annexin V+ CD144+ CD42a- microparticles22.  
 
3.1.3.5 Statistical analysis 
 
Clinical and biochemical parameters and biomarkers (EPC concentration, EPC function, HPC 
number, CEC concentration, and number of endothelial microparticles) were compared between 
CAV negative and CAV positive patients using Instat 3 (GraphPad Software, Inc., San Diego, CA, 
USA). Continuous variables were summarized by means, standard error of the mean, and sample 
size, and were compared by an unpaired t test. Because the distribution of the concentration of 
CECs is heavily right-skewed, a transformation (natural logarithm) was applied and geometric 
means were compared. The Fisher exact test was used to compare categorical data between 
patients with CAV and without CAV. Logistic regression analysis was performed by SAS software, 
version 9.2 (SAS Institute Inc., Cary, NC, USA). The discriminative ability is quantified using the 
concordance statistic (c-statistic), which is equal to the area under the receiver-operating 
characteristic curve. A natural logarithm transformation of CEC data was also applied for logistic 
regression analysis. A p value <0.05 was considered statistically significant. 
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3.1.4 RESULTS 
3.1.4.1 Clinical characteristics of heart transplant recipients with and without CAV 
 
The clinical characteristics of heart transplant recipients are shown in Table 3.1.1. Patients with 
CAV were significantly older at the time of inclusion in the study. There was a trend for a greater 
donor age in patients with CAV, whereas the difference in time after transplantation did not reach 
statistical significance. Donor age correlated moderately with the age of the recipient at the time of 
transplantation (r=0.368; p<0.01). The age of the transplanted heart (sum of donor age and time 
after heart transplantation) was significantly greater in CAV-positive patients (Table 3.1.1). The 
proportion of patients with ischemic heart disease did not differ between both groups. Acute 
rejection episodes (grade ≥3A) were not significantly more frequent in the CAV group than in the 
non-CAV group (Table 3.1.1). The average rejection score of biopsies in the first year also was not 
significantly different between patients without CAV (0.484 ± 0.057) and patients with CAV (0.546 
± 0.057). Creatinine levels were significantly greater in the CAV group than in the non-CAV group 
(Table 3.1.1). Low-density lipoprotein cholesterol in the CAV group was 16% (p<0.05) less than in 
the non-CAV group (Table 3.1.1), which reflects a policy to switch to more potent statins once a 
diagnosis of angiographic CAV is made. The percentage of patients receiving steroids was 3.5-
fold (p<0.01) greater in patients with CAV compared to patients without CAV. 
 
3.1.4.2 EPC number and function do not significantly differ between CAV-negative and 
CAV-positive heart transplant recipients 
 
EPCs were quantified either as the number of Dil-acLDL and FITC-labeled UEA-1 lectin double 
positive cells after 4 days of ex vivo culture or as the number of circulating CD34+ VEGFR-2+ cells. 
Gating strategy and flow cytometry analysis of EPCs are illustrated in Figure 3.1.1. The number of 
FITC labeled UEA-1 lectin double-positive cells was 49% (p<0.0001) less in transplant recipients 
than in healthy controls (Figure 3.1.2A) but did not differ between patients without CAV and with 
CAV (Table 3.1.2). The number of circulating CD34+ VEGFR-2+ cells was similar in healthy 
controls and transplant patients (Figure 3.1.2B) and between CAV-negative and CAV-positive 
transplant recipients (Table 3.1.2). 
EPC migration induced by stromal-derived factor-1α (100 ng/ml) was 31% (p<0.05) less in 
patients than in healthy controls (Figure 3.1.2C). No difference in EPC migration was observed 
between CAV-negative and CAV-positive patients (Table 3.1.2), indicating similar EPC function. 
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Table 3.1.1. Patient characteristics, clinical laboratory parameters, and immunosuppressive 
and hypolipidemic therapy in CAV-negative and CAV-positive heart transplant recipients. 
 Patients without 
CAV (n=22) 
Patients with 
CAV (n=30) 
P 
value 
Age at inclusion in the study (years) 56.3 ± 3.2 64.9 ± 2.1 0.0212 
Sex   1.00 
male 81.8% 80.0% 
female 18.2% 20.0% 
Donor age (years) 33.8 ± 2.9 40.8 ± 2.4 0.0699 
Time after heart transplantation (years) 9.35 ± 0.58 10.9 ± 0.8 0.118 
Age of the transplanted heart (years) 43.2 ± 3.0 51.7 ± 2.3 0.0298 
Sex mismatch graft (%) 13.6% 20.0% 0.716 
Acute rejection episodes (Grade 3A or > 3A) 13.6% 10.0% 0.689 
Ischemic heart disease (%) 36.4% 50.0% 0.402 
Current smoker (%) 13.6% 0% 0.0697 
Hypertension (%) 90.9% 100% 0.174 
Diabetes (%) 18.2% 36.7% 0.217 
Body mass index (kg/m2) 26.6 ± 0.8 25.5 ± 0.5 0.264 
Platelet count (109/L) 232 ± 16 217 ± 12 0.421 
Leukocyte count (109/L) 6.81 ± 0.33 6.87 ± 0.24 0.764 
Monocyte count (109/L) 0.334 ± 0.048 0.313 ± 0.039 0.704 
Lymphocyte count (109/L) 1.24 ± 0.13 1.28 ± 0.12 0.793 
Neutrophil count (109/L) 3.12 ± 0.32 3.78 ± 0.36 0.170 
Creatinine (mg/dl) 1.32 ± 0.10 1.60 ± 0.08 0.0134 
Cholesterol (mg/dl) 168 ± 8 156 ± 6 0.211 
Triglycerides (mg/dl) 108 ± 7 125 ± 12 0.244 
HDL cholesterol (mg/dl) 55.0 ± 2.9 54.2 ± 3.4 0.487 
LDL cholesterol (mg/dl) 91.6 ± 5.7 77.1 ± 4.0 0.0436 
Statins (%) 95.5% 100% 0.423 
Cyclosporine (%) 31.8% 23.3% 0.540 
Tacrolimus (%) 63.6% 70.0% 0.766 
Everolimus (%) 4.55% 20.0% 0.216 
Azathioprine (%) 9.10% 13.3% 1.00 
Mycophenolate mofetil (%) 86.4% 60.0% 0.0622 
Steroid (%) 18.2% 63.3% 0.0018 
Cyclosporine+ Azathioprine (%) 9.09% 0% 0.174 
Cyclosporine+MMF (%) 22.7% 13.3% 0.468 
Tacrolimus+MMF (%) 59.1% 40.0% 0.160 
Everolimus+MMF (%) 4.55% 16.7% 0.225 
Tacrolimus+Everolimus (%) 0% 10.0% 0.253 
Data of continuous variables represent means ± SEM. 
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3.1.4.3 Granulocyte colony-forming units are significantly less in the peripheral blood of 
patients with CAV than in patients without CAV 
 
Figure 3.1.3 compares HPC number between healthy controls and transplant recipients. Erythroid 
burst-forming units, granulocyte, macrophage colony-forming units, macrophage colony-forming 
units, and granulocyte colony-forming units were significantly less in transplant recipients than in 
healthy controls, whereas no significant differences were observed for erythroid colony-forming 
units and granulocyte, erythrocyte, macrophage, megakaryocyte colony-forming units (Figure 
3.1.3). The number of granulocyte colony-forming units was reduced by 59% (p<0.05) in patients 
with CAV compared to patients without CAV but no significant differences were observed in other 
types of colonies (Table 3.1.2). 
 
Table 3.1.2. Comparison of EPC number, EPC function, and HPC number between CAV-
negative and CAV-positive patients. 
 Patients without 
CAV (n=22) 
Patients with CAV 
(n=30) 
P 
value 
Dil-acLDL / lectin+ cells (number/mm2) 13.6 ± 1.9 14.6 ± 1.8 0.685 
CD34+ VEGFR2+ cells (number/µl blood) 2.06 ± 0.46 1.95 ± 0.52 0.875 
Migrated cells (number/mm2) 38.4 ± 3.7 35.1 ± 3.1 0.495 
CFU-E (number per 2 x 105 MNC) 5.20 ± 0.81 5.08 ± 0.81 0.910 
BFU-E (number per 2 x 105 MNC) 17.1 ± 2.1 21.6 ± 2.6 0.180 
CFU-GEMM (number per 2 x 105 MNC) 1.18 ± 0.29 2.08 ± 0.58 0.179 
CFU-GM (number per 2 x 105 MNC) 3.91 ± 0.61 3.53 ± 0.49 0.634 
CFU-M (number per 2 x 105 MNC) 0.750 ± 0.157 0.975 ± 0.342 0.554 
CFU-G (number per 2 x 105 MNC) 0.523 ± 0.125 0.217 ± 0.089 0.0147 
 
CFU-E: erythroid colony-forming units; BFU-E: erythroid burst-forming units; CFU-GEMM: 
granulocyte, erythrocyte, macrophage, megakaryocyte colony-forming units; CFU-GM: 
granulocyte, macrophage colony-forming units; CFU-M: macrophage colony-forming units; 
CFU-G: granulocyte colony-forming units; MNC: mononuclear cells. All data represent 
means ± SEM. 
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Figure 3.1.1. Flow cytometry analysis of EPCs. Gating strategy for EPCs, identified as CD34+ VEGFR-2+ mononuclear cells in whole blood samples (A, B). 
The first gate is set on CD34+ cells out of the mononuclear cellular events (A), which is then displayed on a scatter plot to quantify CD34+ VEGFR-2+ cells (B). 
The isotype control for VEGFR-2 is shown in panel C. Representative contour plots of EPCs in healthy controls, CAV negative transplant recipients, and CAV 
positive transplant recipients are shown in panels D, E, and F, respectively. 
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Figure 3.1.2. Quantification of EPC number and EPC function in healthy controls and 
transplant recipients. EPC number was quantified as the number of Dil-acLDL and FITC labeled 
UEA-1 lectin double positive cells (A) or as the concentration of circulating CD34+ VEGFR2+ cells 
(B). EPC function was evaluated by quantification of EPC migration in modified Boyden chambers 
(C). Comparisons were made between healthy controls (n=25) and transplant recipients (n=52). 
All data represent means ± SEM. 
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Figure 3.1.3. Enumeration of HPCs in healthy controls and transplant recipients. 
Comparison of the number of CFU-E (erythroid colony-forming units) (A), BFU-E (erythroid burst-
forming units) (B), CFU-GEMM (granulocyte, erythrocyte, macrophage, megakaryocyte colony-
forming units) (C), CFU-GM (granulocyte, macrophage colony-forming units) (D), CFU-M 
(macrophage colony-forming units) (E), and CFU-G (granulocyte colony-forming units) (F) 
between healthy controls (n=25) and transplant recipients (n=52). MNC: mononuclear cells. All 
data represent means ± SEM. 
CIRCULATING APOPTOTIC CECs AND APOPTOTIC CEMPs PREDICT PRESENCE OF CAV 
 
 43 
 
3.1.4.4 Circulating apoptotic endothelial cells are significantly greater in patients with 
CAV than in patients without CAV 
 
The geometric mean of the concentration of circulating endothelial (CD45- CD31bright VEGFR-2+) 
cells, apoptotic endothelial (CD45- CD31bright VEGFR-2+ Annexin V positive) cells, and viable 
endothelial (CD45- CD31bright VEGFR-2+ Annexin V negative) cells was increased by 1.7-fold 
(p=0.062), 1.5-fold (p=NS), and 1.8-fold (p=0.053), respectively, in transplant recipients compared 
to healthy controls. (Figure 3.1.4). The geometric mean of total, apoptotic, and viable endothelial 
cells was 2.0-fold (p=0.063), 2.6-fold (p<0.01), and 1.9-fold (p=NS) greater, respectively, in 
patients with CAV compared to patients without CAV (Table 3.1.3). Gating strategy and flow 
cytometry analysis of apoptotic CECs are illustrated in Figure 3.1.5. 
 
3.1.4.5 Circulating apoptotic endothelial microparticles are significantly higher in patients 
with CAV than in patients without CAV 
 
The concentration of circulating endothelial (CD42a- CD144+) microparticles, apoptotic endothelial 
(CD42a- CD144+ Annexin V positive) microparticles, and viable endothelial (CD42a- CD144+ 
Annexin V negative) microparticles was 2.6-fold (p<0.0001), 2.0-fold (p<0.001), and 2.6-fold 
(p<0.0001) greater, respectively, in transplant recipients compared to healthy controls (Figure 
3.1.6). The concentration of total, apoptotic, and viable endothelial microparticles was 1.8-fold 
(p<0.05), 2.0-fold (p<0.01), and 1.7-fold (p<0.05) greater, respectively, in patients with CAV 
compared to patients without CAV (Table 3.1.3). Gating strategy and flow cytometry analysis of 
apoptotic endothelial microparticles are illustrated in Figure 3.1.7. 
 
Table 3.1.3. Comparison of CECs and circulating endothelial microparticles between CAV 
negative and CAV positive patients. 
CEMPs: circulating endothelial microparticles. Data on CECs represent means ± SEM of 
natural logarithm (ln) transformed values. Data on CEMPs represent means ± SEM. 
 Patients without 
CAV (n=22) 
Patients with CAV 
(n=30) 
P value 
Total CECs (ln (number/µl blood)) -0.268 ± 0.266 0.429 ± 0.251 0.0627 
Apoptotic CECs (ln (number/µl blood)) -2.07 ± 0.25 -1.11 ± 0.26 0.0099 
Viable CECs (ln (number/µl blood)) -0.502 ± 0.281 0.114 ± 0.256 0.111 
Total CEMPs (number/µl plasma) 41.4 ± 9.96 72.7 ± 11.0 0.0400 
Apoptotic CEMPs (number/µl plasma) 4.06 ± 0.52 8.02 ± 1.18 0.0039 
Viable CEMPs (number/µl plasma) 37.3 ± 9.60 64.7 ± 10.6 0.0410 
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Figure 3.1.4. Quantification of circulating endothelial cells (CECs) by flow cytometry in 
healthy controls and transplant recipients. Circulating endothelial cells (CECs) (A), apoptotic 
CECs (B), and viable CECs (C) were compared between healthy controls (n=25) and transplant 
recipients (n=52). All data represent means ± SEM of natural logarithm (ln) transformed values. 
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Figure 3.1.5. Flow cytometry analysis of CECs. Gating strategy for CECs, identified as CD45- 
CD31bright VEGFR-2+ mononuclear cells in whole blood samples (A, B, C). An initial gate is set on 
CD45- cells out of the mononuclear cellular events (A). Next, a second gate is set on CD45- 
CD31bright cells (B), which is further displayed on a FACS scatter plot to identify CD45- CD31bright 
VEGFR-2+ cells (C). The isotype control for VEGFR-2 is shown in panel D. Representative contour 
plots of Annexin V positive circulating endothelial cells in healthy controls, CAV negative transplant 
recipients, and CAV positive transplant recipients are shown in panels E, F, and G, respectively. 
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Figure 3.1.6. Determination of circulating endothelial microparticles by flow cytometry in 
healthy controls and transplant recipients. Circulating endothelial microparticles (CEMPs) (A), 
apoptotic CEMPs (B), and viable CEMPs (C) were analysed in healthy controls (n=25) and 
transplant recipients (n=52). All data represent means ± SEM. 
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Figure 3.1.7. Flow cytometry analysis of circulating endothelial microparticles. Gating 
strategy for endothelial microparticles in human plasma, identified as CD42a- CD144+ 
microparticles (A). The isotype control for CD144 is shown in panel B. Representative contour 
plots for Annexin V positive endothelial microparticles in healthy controls, transplant recipients 
without CAV, and transplant recipients with CAV are shown in panels C, D, and E, respectively. 
 
3.1.4.6 Discrimination between CAV-positive and CAV-negative transplant recipients 
based on logistic regression and receiver-operating characteristic analysis 
 
Table 3.1.4 summarizes c-statistic values of univariable models. The odds ratio per standard 
deviation increase of apoptotic CECs (natural logarithm transformed) and of apoptotic endothelial 
microparticles was 2.32 (95% CI: 1.14-4.71; p=0.0196) and 3.24 (1.17 to 8.96; p=0.0234), 
respectively. The receiver-operating characteristic curve for the logistic regression function 
containing apoptotic CECs and apoptotic endothelial microparticles as independent predictors is 
shown in Figure 3.1.8. The c-statistic was 0.812 (95% CI: 0.692 to 0.932).  
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Figure 3.1.8. Receiver-operating characteristic curve for the logistic regression model with 
apoptotic CECs and apoptotic endothelial microparticles as predictors. This receiver 
operating characteristic curve illustrates the discriminative ability of the two new biomarkers 
investigated in the current study. The area under this curve is equal to the c-statistic. AUC = area 
under the curve; CEC = circulating endothelial cell; CI = confidence interval. 
 
In a logistic regression model with recipient age and creatinine as covariates, apoptotic CECs and 
apoptotic endothelial microparticles added significant information (chi-square=18.4; df=2; 
p=0.0001) and were both independent predictors (Table 3.1.5). The c-statistic corresponding to 
this model was 0.855 (95% CI: 0.756 to 0.953). When recipient age in these models was 
substituted by time after heart transplantation or age of the transplanted heart, results were 
essentially unaltered (data not shown). 
When steroid dose was introduced in the model, apoptotic CECs and apoptotic endothelial 
microparticles remained independent predictors (data not shown). The c-statistic corresponding to 
this model was 0.926 (95% CI: 0.851 to 1.00). There was significant added value of introduction of 
apoptotic CECs together with endothelial apoptotic microparticles in the model with age, 
creatinine, and steroid dose (chi-square =16.3; df=2; p=0.0003). 
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Table 3.1.4. Discrimination between CAV-positive and CAV-negative transplant recipients 
based on receiver operating characteristic (ROC) analysis. 
 c-statistic 
Age 0.689 (0.537-0.842) 
Creatinine 0.703 (0.552-0.854) 
LDL cholesterol 0.660 (0.507-0.813) 
Steroid dose 0.758 (0.642-0.873) 
CFU-G 0.681 (0.547-0.815) 
Apoptotic CECs 0.709 (0.567-0.851) 
Apoptotic CEMPs 0.697 (0.554-0.840) 
The c-statistic corresponds to the area under the ROC curve. The 95% confidence interval 
is indicated between brackets. CEC: circulating edothelial cell. CEMP: circulating 
endothelial microparticle. 
 
 
Table 3.1.5. Logistic regression model for prediction of CAV. 
 OR P value 
Age (years) 1.38 (0.66-2.88) 0.399 
Creatinine (mg/dL) 3.50 (1.27-9.66) 0.0158 
Apoptotic CECs (ln number/µl) 4.34 (1.40-13.5) 0.0112 
Apoptotic CEMPs (number/100 µl) 5.30 (1.40-20.0) 0.0141 
The 95% confidence interval is indicated between brackets. Odds ratios (OR) are 
expressed per standard deviation increase. CEC: circulating edothelial cell. CEMP: 
circulating endothelial microparticle. 
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3.1.5 DISCUSSION 
 
This is the first study to demonstrate that apoptotic CECs and apoptotic endothelial microparticles 
are independent predictors of CAV and that the combination of these two biomarkers has a high 
discriminative ability between patients without CAV and with CAV. 
 
3.1.5.1 Clinical parameters and CAV 
 
A salient finding of the current study is that steroid use was more prevalent in CAV-positive 
patients than in CAV-negative patients. This is in line with a report of the Stanford group in 200423 
in a population of patients on an immunosuppressive background therapy predominantly 
comprising cyclosporine and azathioprine. Our observation cannot be explained by a continuation 
of steroids following severe acute rejection episodes in the first year, since the proportion of 
patients with severe acute rejection episodes in the first year was similar in patients with CAV 
compared to patients without CAV. Second, difference of steroid use can also not be the result of 
tailoring of therapy according to renal function since creatinine levels were not different between 
steroid users and non-steroid users (data not shown). On the other hand, the time after heart 
transplantation was significantly (p<0.05) longer in patients on steroids  (11.6 ± 0.9 years) 
compared to non-steroid users (9.1 ± 0.5 years). This reflects an evolution to steroid free 
immunosuppressive regimens in more recently transplanted patients. However, steroid use was 
also predictive of the presence of CAV in models in which the time after transplantation was 
introduced as a covariate. Therefore, we cannot exclude the possibility that continued steroid use 
plays a causative role in the development of CAV. 
Impaired renal function was an independent predictor of the presence of CAV. The natural history 
of renal function following heart transplantation is characterised by a decline in renal function24. 
Age, pre-transplant glomerular filtration rate, pre-transplant diabetes, and pre-transplant 
hypertension are important risk factors for a decrement of renal function24. Nephrotoxicity of 
calcineurin inhibitors is largely responsible for the progressive development of renal 
dysfunction25,26. Our results are in line with those of Schober et al.27. However, impaired renal 
function was not a predictor in a study with angiographic follow-up limited to 4 years28. 
The observation that time after transplantation does not predict the CAV status may seem illogical. 
However, the recruitment of patients in the current study was restricted to heart transplant 
recipients between 5 and 15 years after transplantation undergoing coronary angiography during 
follow-up. Because of this selection procedure, time after transplantation tends to be similar in the 
CAV-positive and CAV-negative patients. 
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3.1.5.2 Biomarkers of endothelial repair and CAV 
 
We did not observe a difference between CAV-positive and CAV-negative patients in the number 
of EPCs quantified as the number of CD34+ VEGFR-2+ cells by flow cytometry analysis or as the 
number of Dil-acLDL and FITC-labeled UEA-1 lectin double positive cells after 4 days of ex vivo 
culture. Furthermore, EPC function was similar in patients with CAV and without CAV. In contrast, 
Simper and colleagues29 observed that the number of EPC colony-forming units (late outgrowth 
EPCs) appearing over a 6-week culture period was significantly lower in 8 patients with CAV 
compared to 7 patients without CAV. However, our results are in line with those of Thomas et al.30 
and Schober et al.27 who quantified EPC count as the number of CD34+ VEGFR-2+ cells. 
Interestingly, Schober et al.27 demonstrated that the number of CD34+ CD140b+ smooth muscle 
progenitor cells is independently associated with the presence of CAV. 
EPC number based on ex vivo culture assay was lower and EPC function was impaired in 
transplant recipients compared to healthy controls. Different classes of immunosuppressive drugs 
may affect EPC biology31,32. Therefore, the lack of discriminative ability of EPC number and EPC 
function to detect the presence of CAV may be related to a generalized impairment of these 
parameters in heart transplant recipients receiving different classes of immunosuppressive drugs. 
In contrast, in a murine model of transplant vasculopathy without immunosuppression, increased 
EPC number and enhanced EPC function attenuated progression of the disease33,34.  
Because the term EPC is used in a very broad sense in the literature, EPCs encompass different 
categories of cells with different phenotypic and functional properties that affect neovascularization 
and reendothelialization. A salient observation in the current study is that EPC number defined as 
CD34+ VEGFR-2+ cells did not differ between healthy controls and transplant recipients in contrast 
to EPC number determined by ex vivo cell culture. This basically reflects that the same term is 
used for entirely different categories of cells. Many so-called EPCs are in fact hematopoietic 
lineage cells. Hematopoietic progenitor cells may differentiate into proangiogenic cells12 and may 
promote neovascularization and endothelial repair in a paracrine way. HPC culture assays showed 
a significantly lower number of granulocyte colony-forming units in the peripheral blood of CAV-
positive compared to CAV-negative patients. However, in multivariate logistic regression, the 
number of granulocyte colony-forming units was not an independent predictor of the presence of 
CAV (data not shown). Taken together, biomarkers of endothelial repair that were evaluated in the 
current study are not suited for clinical prediction models of CAV. However, we cannot exclude 
that other assays of endothelial repair discriminate between CAV-negative and CAV-positive 
patients in multivariable models. 
 
3.1.5.3 Biomarkers of endothelial injury and CAV 
 
The concentration of apoptotic endothelial microparticles and of apoptotic CECs was significantly 
different between CAV-positive and CAV-negative patients. As indicated by the c-statistic value of 
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0.812, the logistic regression model combining these two biomarkers provides high discriminative 
ability between CAV-positive and CAV-negative patients. 
In several logistic regression models, the introduction of apoptotic CECs and apoptotic endothelial 
microparticles consistently resulted in added value, indicating that these biomarkers are robust 
independent predictors. Whereas the final model in the current study is restricted to age, 
creatinine, apoptotic CECs, and apoptotic endothelial microparticles, the latter two parameters 
remain significant predictors in models with creatinine and steroid dose. Importantly, the 
discriminative ability of these two biomarkers was also preserved in models in which recipient age 
was replaced by time after transplantation or by age of the transplanted heart. 
 
3.1.5.4 Study limitations 
 
Because the number of subjects in the current study is limited to 22 CAV-negative patients and 30 
CAV-positive patients, models with more than 3 predictors should be interpreted with caution35. 
Inclusion of too many predictors leads to overfitting of the data and C-indices are overestimated35. 
However, the additional models strongly suggest that the discriminative ability of apoptotic 
endothelial microparticles and apoptotic CECs is not affected by potential confounders such as 
age, renal function, and steroid dose. 
Annexin V positivity, corresponding to phosphatidylserine externalization, should be interpreted 
with caution. It is already positive in an early and potentially reversible stage of apoptosis36,37 and 
is not entirely specific for apoptosis38,39. However, these issues do not undermine the 
discriminative ability of Annexin V positive categories that were evaluated in the current study. 
 
3.1.5.5 Future studies 
 
The high discriminative ability of apoptotic CECs and apoptotic endothelial microparticles provides 
a solid foundation for the further development of clinical prediction models of CAV in the 
framework of prospective studies that evaluate CAV by coronary intravascular ultrasound. 
Prospective prediction models may lead to a more rational and more tailored use of coronary 
angiography and intravascular ultrasound that are not without risk. In addition, risk prediction 
models may allow quicker intervention and may help in the design of new randomized clinical trials 
to optimize therapy in heart transplant recipients. 
 
3.1.6 CONCLUSIONS 
 
Apoptotic CECs and apoptotic endothelial microparticles predict the presence of CAV independent 
of the age of the recipient, age of the transplanted heart, creatinine level, steroid use, and number 
of granulocyte colony-forming units. The results of the current study are compatible with the 
hypothesis that endothelial activation and injury are involved in the development of CAV.  
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3.2 MARKERS OF ENDOTHELIAL INJURY AND PLATELET 
MICROPARTICLES ARE DISTINCT IN PATIENTS WITH 
STABLE NATIVE CORONARY ARTERY DISEASE AND WITH 
CARDIAC ALLOGRAFT VASCULOPATHY*
3.2.1 ABSTRACT 
 
 
Background: Endothelial injury plays a key role in both native coronary artery disease (CAD) and 
cardiac allograft vasculopathy (CAV). Cellular biomarkers of endothelial injury (circulating 
endothelial microparticles (CEMPs) and circulating endothelial cells (CECs)) may discriminate 
between endothelial activation and irreversible endothelial damage. The hypothesis that 
endothelial injury and circulating platelet microparticles (CPMPs) are distinct in both types of 
arteriosclerosis was investigated.  
Methods and Results: The geometric mean of the concentration of CECs (CD45- CD31bright 
VEGFR-2+) was 2.90-fold (p<0.001) and 2.34-fold (p<0.05) higher in patients with stable native 
CAD (n=80) and with CAV (n=30), respectively, compared to healthy controls (n=25). No 
significant difference in total, Annexin V negative, and Annexin V positive (apoptotic) CECs was 
observed between patients with native CAD and with CAV. The concentration of Annexin V 
negative CEMPs (CD144+ CD42a-) was 59.2% (p<0.01) higher in transplant recipients with CAV 
than in native CAD patients but no difference in Annexin V positive CEMPs was observed. The 
median value of total CD61+ CPMPs in native CAD patients was 69.4% (p<0.001) and 71.6% 
(p<0.001) lower compared to healthy controls and transplant recipients with CAV, respectively. 
These differences were even more pronounced when CD42a+CD31+ CPMPs were quantified. 
Conclusion: The selective increase of Annexin V negative CEMPs and the absence of a 
difference in Annexin V positive CECs strongly suggest increased endothelial activation but not 
endothelial apoptosis in CAV positive patients compared to stable CAD patients. Use of 
antiplatelet drugs likely underlies the strikingly lower levels of CPMPs in patients with native CAD. 
 
3.2.2 INTRODUCTION 
 
Cardiac allograft vasculopathy (CAV) is a particular type of arteriosclerosis with many similarities 
but also significant differences compared to native coronary artery disease (CAD). Atherosclerosis 
in patients with stable native CAD is characterized by the presence of atheromata that contain a 
lipid core filled with extracellular cholesterol and cellular debris and are covered by a fibrous cap. 
In contrast, fibromuscular intimal hyperplasia is the most prominent lesion type of CAV and mainly 
consists of smooth muscle cells and extracellular matrix1. It tends to be circumferential and not 
                                                 
* This chapter has been published as: Singh, N., Vanhaecke, J., Van Cleemput, J., De Geest, B.. 
Markers of endothelial injury and platelet microparticles are distinct in patients with stable native 
coronary artery disease and with cardiac allograft vasculopathy. International Journal of 
Cardiology 2015; 179, 331-333 
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only involves the proximal part of epicardial arteries but also smaller epicardial arteries and 
intramyocardial arteries.  
Endothelial injury is assumed to play a key role in the initiation and progression of both native CAD 
and CAV2, 3. In the response-to-injury hypothesis of atherosclerosis of Ross and Glomset, 
endothelial injury was originally defined as endothelial denudation resulting from focal 
desquamation of endothelium4, 5. Later versions of the response-to-injury hypothesis emphasized 
endothelial dysfunction rather than denudation2, 6. Biochemical surrogate biomarkers of endothelial 
injury (e.g. von Willebrand factor, soluble thrombomodulin, soluble vascular cell adhesion 
molecule, soluble intercellular adhesion molecule, and soluble E-selectin) do not discriminate 
between endothelial activation and irreversible endothelial damage and lack endothelial 
specificity7. In contrast, cellular biomarkers of endothelial injury (circulating endothelial 
microparticles (CEMPs) and circulating endothelial cells (CECs)) are endothelial-specific. 
Microparticles are 0.1 µm to 1 µm large membrane vesicles that are released following cell 
activation or apoptosis8. Levels of CEMPs inversely correlate with the amplitude of flow-mediated 
dilatation9-12 indicating that they are a valid biomarker of endothelial function. In contrast to 
CEMPs, CECs constitute a parameter of irreversible damage of the endothelium13-15. CECs are 
mature endothelial cells that originate by detachment from the endothelial monolayer as a result of 
an endothelial insult. Thus, by combined quantification of CEMPs and CECs, it is possible to 
evaluate to which extent endothelial injury represents endothelial activation or endothelial 
denudation. Since the lesions of native CAD and CAV are clearly different, the primary hypothesis 
investigated in the current study was whether a distinct pattern of endothelial injury (endothelial 
activation versus endothelial denudation) would be observed in these two types of arteriosclerosis. 
Platelets can adhere to dysfunctional endothelium, exposed collagen, and macrophages, and 
promote initiation and progression of atherosclerosis2, 5. Platelet microparticles are a marker of 
platelet activation. The secondary objective of the current study was to compare circulating platelet 
microparticles (CPMPs) in patients with native CAD and with CAV. 
 
3.2.3 METHODS 
 
3.2.3.1 Study design 
 
Eighty patients with clinically stable native coronary artery disease (CAD) and thirty heart 
transplant recipients with cardiac allograft vasculopathy (CAV) were recruited in the current cross-
sectional study. Stable native CAD patients were defined by the presence of at least one stenosis 
of 50% or more demonstrated by diagnostic coronary angiography. CAV was diagnosed in heart 
transplant recipients undergoing coronary angiography between 5 and 15 years after heart 
transplantation16. CAV was graded according to the International Society for Heart and Lung 
Transplantation working formulation of a standardized nomenclature for CAV-201017. The study 
protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected by 
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the a priori approval of the protocol by the Ethics Committee of the University Hospital 
Gasthuisberg. Written informed consent was obtained from all participants. The reference control 
group included 25 healthy control subjects (12 males and 13 females). Average age of healthy 
controls was 43.2 ± 2.0 years. 
 
3.2.3.2 Determination of the number of circulating endothelial cells, endothelial 
microparticles, and platelet microparticles by flow cytometry 
 
Circulating endothelial cells (CECs) were defined as CD45- CD31bright VEGFR-2+ mononuclear 
cells as described by Duda et al.18. Platelet-poor plasma derived from sodium citrate 
anticoagulated blood was used for microparticle quantification by flow cytometry analysis. 
Circulating endothelial microparticles (CEMPs) were defined as CD144 (VE-Cadherin)+ CD42a 
(GPIX)- microparticles as described before16. Circulating platelet microparticles (CPMPs) were 
determined as CD61+ microparticles19, 20 or alternatively as CD31+ CD42a+ microparticles21, 22. 
Annexin V (Immunotools, Friesoythe, Germany) staining was used to discriminate between 
apoptotic and non-apoptotic microparticles. For CPMPs quantification, incubation of platelet-poor 
plasma was performed with mouse monoclonal antibodies directed against human CD61 
(Biolegend, San Diego, California, USA), human CD31 (BD Biosciences, San Jose, California, 
USA), and human CD42a (BD Biosciences, San Jose, California, USA), and with Annexin V. 
Samples were acquired on a low flow rate (30 µl/min) for 5 minutes using a BD FACSCantoII flow 
cytometer and BD FACSDIVA software version 1.2.6 (BD Biosciences). 
 
3.2.3.3 Statistical analysis 
 
Clinical and laboratory parameters were compared between stable native CAD patients and CAV 
positive patients using Instat 3 (Graphpad software, San Diego, CA, USA). Continuous variables 
were summarized by means, standard error of the mean, and sample size, and were compared 
between two groups by Student t-test or if indicated a Mann-Whitney test was applied. Fisher’s 
exact test was used to compare the categorical data between stable native CAD patients and CAV 
positive patients. CECs, CEMPs, and CPMPs were compared between healthy controls, stable 
native CAD patients, and heart transplant recipients with CAV by analysis of variance followed by 
Tukey’s post hoc test. If indicated, a logarithmic transformation of the data was performed or a 
Kruskal-Wallis test followed by Dunn’s post hoc test was applied. A p-value of less than 0.05 was 
considered statistically significant. 
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3.2.4 RESULTS 
 
3.2.4.1 Patient characteristics 
 
Clinical characteristics, laboratory parameters, and medical therapy in patients with stable native 
CAD (n=80) and heart transplant recipients with CAV (n=30) are summarized in Table 3.2.1. 
Patients with native CAD were 4.7 years (p<0.05) older, had a lower prevalence of hypertension 
(p<0.0001), and a higher body mass index than patients with CAV (p<0.05). C-reactive protein 
levels were 6.32-fold (p<0.001) higher in heart transplant recipients with CAV than in patients with 
native CAD. Lipoprotein levels were very similar and statin use was generalized in both conditions. 
The use of antiplatelet drugs was generalized in patients with native CAD and was restricted to 
one heart transplant recipient with CAV. 
 
3.2.4.2 Circulating endothelial cells are increased in stable native CAD patients and heart 
transplant recipients with CAV to a similar extent 
 
The geometric mean of the concentration of circulating endothelial (CD45- CD31bright VEGFR-2+) 
cells (CECs) was increased 2.90-fold (p<0.001) and 2.34-fold (p<0.05) in patients with native CAD 
and with CAV, respectively, compared to healthy controls (Figure 3.2.1A). The elevation of 
Annexin V negative CECs and Annexin V positive CECs in patients with native CAD and CAV 
compared to healthy controls is illustrated in Figure 3.2.1B and 3.2.1C, respectively. No significant 
differences in any of these parameters were observed between patients with native CAD and 
transplant recipients with CAV. Taken together, the number of CECs as a parameter of irreversible 
endothelial damage is similarly increased in both types of arteriosclerosis. 
 
3.2.4.3 Total endothelial microparticles and Annexin V negative endothelial microparticles 
are higher in transplant recipients with CAV than in patients with native CAD 
 
Circulating endothelial (CD42a- CD144+) microparticles (CEMPs), Annexin V negative CEMPs, 
and Annexin V positive CEMPs were elevated in patients with native CAD and transplant 
recipients with CAV compared to healthy controls as illustrated in Figure 3.2.2A, Figure 3.2.2B, 
and Figure 3.2.2C, respectively. The concentration of CEMPs (Figure 3.2.2A) and Annexin V 
negative CEMPs (Figure 3.2.2B) was 45.8% (p<0.01) and 59.2% (p<0.01) higher, respectively, in 
transplant recipients with CAV than in patients with native CAD. No significant difference in 
Annexin V positive CEMPs was observed between patients with native CAD and CAV (Figure 
3.2.2C). Taken together, the selective increase of Annexin V negative CEMPs in transplant 
recipients with CAV compared to patients with native CAD is compatible with more pronounced 
endothelial cell activation in the former. 
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Table 3.2.1. Clinical characteristics, laboratory parameters, and hypolipidemic and 
antiplatelet therapy in patients with stable native CAD and in transplant recipients with 
CAV. 
 Patients with stable 
native CAD 
(n=80) 
Patients with CAV 
(n=30) 
P value 
Age at inclusion in the 
study (years) 
69.6 ± 1.2 64.9 ± 2.1 0.0459 
Sex (male/female) 63 (78.8%)/17 (21.3%) 24 (80.0%)/6 (20.0%) 1.00 
Current smoker (%) 7.5% 0% 0.186 
Hypertension (%) 47.5% 100% <0.0001 
Diabetes (%) 25.0% 36.7% 0.242 
Body mass index (kg/m2) 27.5 ± 0.6 25.5 ± 0.5 0.0337 
Platelet count (109/L) 222 ± 5 217 ± 12 0.150 
Leukocyte count (109/L) 7.19 ± 0.22 6.87 ± 0.24 0.398 
Monocyte count (109/L) 0.435 ± 0.029 0.313 ± 0.039 0.012 
Lymphocyte count (109/L) 1.94 ± 0.08 1.28 ± 0.12 <0.0001 
Neutrophil count (109/L) 4.22 ± 0.20 3.78 ± 0.36 0.213 
Creatinine (mg/dl) 1.05 ± 0.03 1.60 ± 0.08 <0.0001 
CRP (mg/l) 1.95 ± 0.18 12.4 ± 3.3 <0.0001 
Cholesterol (mg/dl) 160 ± 4 156 ± 6 0.548 
Triglycerides (mg/dl) 132 ± 7 125 ± 12 0.557 
HDL cholesterol (mg/dl) 50.2 ± 1.8 54.2 ± 3.4 0.353 
LDL cholesterol (mg/dl) 83.6 ± 3.0 77.1 ± 4.0 0.402 
Acetylsalicylic acid (%) 88.8% 3.33% <0.0001 
Statins (%) 95.0% 100% 0.573 
Clopidogrel (%) 13.8% 0% 0.0334 
Data are expressed as means ± SEM for continuous variables. 
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Figure 3.2.1. Individual value bar graph representing a comparison of total circulating endothelial 
cells (CECs) (panel A), Annexin V- CECs (panel B) and Annexin V+ CECs (panel C) in healthy 
controls (n=25), stable native CAD patients (n=80), and heart transplant recipients with CAV 
(n=30). Data points show the individual natural logarithm (ln) transformed values. Means of ln 
transformed values are shown by the horizontal lines. 
 
MARKERS OF ENDOTHELIAL INJURY ARE DISTINCT IN CAD AND CAV 
 
 63 
 
 
 
Figure 3.2.2. Individual value bar graph illustrating a comparison of total circulating endothelial 
microparticles (CEMPs) (panel A), Annexin V- CEMPs (panel B) and Annexin V+ CEMPs (panel C) 
in healthy controls (n=25), stable native CAD patients (n=80), and heart transplant recipients with 
CAV (n=30). Data points show the individual values. Means are shown by the horizontal lines. 
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3.2.4.4 Platelet microparticles are strikingly lower in patients with native CAD 
 
Circulating platelet (CD61+) microparticles (CPMPs), Annexin V negative CD61+ CPMPs, and 
Annexin V positive CD61+ CPMPs were significantly lower in patients with native CAD compared 
to healthy controls and transplant recipients with CAV as illustrated in Figure 3.2.3A, Figure 
3.2.3B, and Figure 3.2.3C, respectively. The median value of total CD61+ CPMPs in patients with 
native CAD was 69.4% (p<0.001) and 71.6% (p<0.001) lower compared to healthy controls and 
transplant recipients with CAV, respectively. This decline was observed both for Annexin V 
negative CD61+ CPMPs (Figure 3.2.3B) and Annexin V positive CD61+ CPMPs (Figure 3.2.3C). No 
difference in any of these parameters was observed between healthy controls and transplant 
recipients with CAV. 
To confirm these pronounced differences, we additionally quantified the number of CD42a+CD31+ 
CPMPs. The median value of CD42a+CD31+ CPMPs in patients with native CAD was decreased 
by 95.9% (p<0.001) and by 89.2% (p<0.001) compared to healthy controls and heart transplant 
recipients with CAV, respectively (Figure 3.2.4A). Similarly to the decline of total CD42a+CD31+ 
CPMPs, Annexin V negative CD42a+CD31+ CPMPs (Figure 3.2.4B) and Annexin V positive 
CD42a+CD31+ CPMPs (Figure 3.2.4C) were greatly reduced in patients with native CAD 
compared to healthy controls and patients with CAV. 
Since all patients with native CAD and only one patient with CAV were taking antiplatelet drugs, 
this suggested that the observed difference in CPMPs is due to this class of medication. The 
concentration of CD61+ CPMPs (60.8/µl) and CD42a+CD31+ CPMPs (138/µl) in the CAV patient 
taking acetylsalicylic acid was in the order of magnitude of patients with native CAD (Figure 3.2.3A 
and 3.2.3B). To further confirm the effect of acetylsalicylic acid on CPMPs, an additional 
quantification was performed in 11 heart transplant recipients taking this drug. The median value 
and distribution (not shown) of CD61+ CPMPs (53.0/µl) and of CD42a+CD31+ CPMPs (71.2/µl) in 
these heart transplant recipients was similar compared to patients with native CAD (Figure 3.2.3A, 
Figure 3.2.4A). In addition, the concentration of CD61+ CPMPs (65.7/µl and 74.3/µl) and of 
CD42a+CD31+ CPMPs (52.3/µl and 56.2/µl) in two heart transplant recipients taking clopidogrel 
were close to the median values in patients with native CAD. All in all, very low concentrations of 
CPMPs in patients with native CAD very likely reflect intake of antiplatelet drugs. 
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Figure 3.2.3. Individual value bar graph showing a comparison of CD61+ platelet microparticles 
(panel A), CD61+ Annexin V- platelet microparticles (panel B) and CD61+ Annexin V+ platelet 
microparticles (panel C) in healthy controls (n=25), stable native CAD patients (n=80), and heart 
transplant recipients with CAV (n=30). Data points show the individual values. Medians are shown 
by the horizontal lines. 
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Figure 3.2.4. Individual value bar graph demonstrating a comparison of CD42a+ CD31+ platelet 
microparticles (panel A), CD42a+ CD31+ Annexin V- platelet microparticles (panel B) and CD42a+ 
CD31+ Annexin V+ platelet microparticles (panel C) in healthy controls (n=25), stable native CAD 
patients (n=80), and heart transplant recipients with CAV (n=30). Data points show the individual 
values. Medians are shown by the horizontal lines. 
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3.2.4.5 Evaluation of the relation of CECs, CEMPs, and CPMPs with clinical and 
laboratory parameters in patients with native CAD and transplant recipients with 
CAV 
 
The relation between age, diabetes status, sex, creatinine levels, body mass index, and C-reactive 
protein levels on the one hand, and end-point parameters on the other hand was evaluated in 
patients with native CAD. The median value of total CD61+ CPMPs was significantly higher 
(p<0.05) in women (61.7/µl) compared to men (43.3/µl). The median values of total CD42a+CD31+ 
CPMPs (43.8/µl versus 32.3/µl), Annexin V negative CD42a+CD31+ CPMPs (22.8/µl versus 
15.0/µl), and Annexin V positive CD42a+CD31+ CPMPs (22.3/µl versus 15.8/µl) were significantly 
higher (p<0.05) in women compared to men. CD61+ Annexin V- CPMPs showed a weak positive 
correlation (r=0.280; p=0.0118) with body mass index in patients with native CAD. Total 
CD42a+CD31+ CPMPs and Annexin V+ CD42a+CD31+ CPMPs weakly positively correlated with C-
reactive protein levels (r=0.260; p=0.0199 and r=0.360; p=0.0010, respectively). Other 
comparisons did not show statistically significant differences in patients with native CAD. 
In transplant recipients with CAV, a positive correlation was observed between creatinine levels 
and total CECs (r=0.421; p=0.0205), Annexin V negative CECs (r=0.381; p=0.0377), and Annexin 
V positive CEC (r=0.466; p=0.0095). In contrast, creatinine levels correlated negatively with total 
CEMPs (r=-0.390; p=0.0331) and Annexin V negative CEMPs (r=-0.385; p=0.0358). No other 
relationship was statistically significant. 
 
3.2.5 DISCUSSION 
 
The salient findings of the current study are that 1) patients with CAV display a distinct pattern of 
endothelial injury compared to patients with native CAD characterized by a more prominent 
increase of total CEMPs but a similar elevation of total CECs compared to healthy controls; 2) the 
selective increase of Annexin V negative CEMPs and the absence of a difference in Annexin V 
positive CECs strongly suggest increased endothelial cell activation but not endothelial cell 
apoptosis in CAV positive patients compared to stable CAD patients and 3) CPMPs are not 
elevated in transplant recipients with CAV compared to healthy controls and are markedly lower in 
patients with native CAD most probably as a result of generalized use of antiplatelet drugs. 
Since CEMPs were higher in transplant recipients with CAV than in patients with native CAD 
whereas CECs were similar, the results of the current study are consistent with increased 
endothelial cell activation in the former. The endothelium regulates vascular tone, inflammation, 
smooth muscle cell proliferation, and thrombosis23. Endothelial dysfunction is considered to be 
pivotal in the pathogenesis of native CAD and CAV2, 3. It is characterized by loss of endothelium-
dependent vasorelaxation, deprivation of anticoagulant, anti-inflammatory and antithrombotic 
properties, absence of antiproliferative effects on smooth muscle cells, and increased endothelial 
permeability. Endothelial dysfunction is paralleled by a switch from a quiescent to an activated 
phenotype characterized by expression of adhesion molecules, cytokines, chemokines, and 
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expression of major histocompatibility class (MHC II) molecules3, 24. Both native CAD and CAV are 
considered to be immune diseases3, 15, 24. However, the main antigens driving atherosclerosis are 
likely modified low density lipoproteins25 whereas the principal antigen in CAV are nonself major 
histocompatibility complex molecules, especially HLA-DR, that are most abundantly expressed on 
luminal endothelial cells26, 27. Activated T cells in the subendothelium of allografts release 
cytokines including interferon-γ that promote endothelial cell activation27. Consistent with the 
different nature of the antigen, the inflammatory infiltrate is localized in the subendothelium in CAV 
whereas T cells and macrophages are largely localized in the shoulder regions of atheromata27. 
The higher degree of endothelial cell activation in CAV as evidenced by increased CEMPs may 
reflect both the localization and the nature of the alloantigen eliciting an adaptive immune 
response. 
To further investigate a distinct pattern of endothelial injury in patients with native CAD and in 
transplant recipients with CAV, Annexin V negative CEMPs and Annexin V positive CEMPs were 
quantified. It has been proposed that not only cells undergoing apoptosis but also activated cells 
are characterized by a loss of asymmetry of normal cell membrane phospholipids, resulting in an 
increase of phosphatidylserine on the outer leaflet of the bilipid cell membrane28. At least 
theoretically, endothelial cell activation may also give rise to Annexin V positive CEMPs. However, 
the large majority of CEMPs in the current study as well as in previous studies are Annexin V 
negative29. This suggests that the in vivo vesiculation process causing microparticle formation in 
activated endothelial cells can occur independently of membrane asymmetry loss30. In agreement 
with this, it has been shown that Annexin V binding sites on endothelial cells occur only in 
apoptosis31. Taken together, the selective increase of Annexin V negative CEMPs in transplant 
recipients with CAV compared to native CAD patients strongly suggests a difference in endothelial 
cell activation but no difference in endothelial cell apoptosis. This is consistent with the 
observation that no significant difference in Annexin V positive CECs was observed. The absence 
of increased endothelial cell apoptosis in CAV may be surprising in light of the alloimmune 
response against endothelial cells. However, there is little evidence for cytolysis in CAV lesions. 
Cytotoxicity is typically mediated by CD8 expressing T cells but apparently, activated T cells in 
CAV are cytokine-producing CD4+ cells27. 
Sloughing off endothelial cells may not only occur by apoptosis but also as a result of 
biomechanical injury, defective adhesive properties of endothelial cells, or protease- or cytokine 
mediated detachment14. The data on Annexin V negative CECs indicate no difference in non-
apoptotic endothelial cell detachment between patients with CAV and with native CAD. Taken 
together, irreversible endothelial damage is similar in both conditions. 
The interaction of platelets with endothelial cells and leukocytes is considered to be important for 
the initiation and progression of atherogenesis32. Quiescent endothelial cells counteract platelet 
adhesion via production of nitric oxide and of prostacyclin and via the ecto-
ADPase/CD39/NTPDase pathway33. These anti-adhesive properties are lost in activated 
endothelium. Activated platelets may promote atherosclerosis or fibromuscular intimal hyperplasia 
via release of mitogenic and inflammatory mediators34. Endothelial-bound platelets are highly 
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effective at recruiting leukocytes from flowing blood35. CPMPs are the most abundant microparticle 
subtype36, 37. A remarkable finding of the current study is that CPMPs were not increased at all in 
heart transplant recipients with CAV compared to healthy controls. Furthermore, levels of CD61+ 
CPMPs were markedly lower and levels of CD42a+CD31+ CPMPs were dramatically lower in 
patients with stable native CAD compared to CAV-positive patients and healthy controls. The 
much more pronounced decline of CD42a+CD31+ CPMPs might be in part related to shedding of 
the von Willebrand Factor receptor complex (glycoprotein Ib-V-IX) via ADAM17 induced by 
acetylsalicylic acid38. However, it is rather unlikely that this particular mechanism occurs at the low 
dosages of acetylsalicylic acid taken by these patients. This is corroborated by the observation 
that similar values of CD42a+CD31+ CPMPs were observed in two heart transplant recipients 
taking clopidogrel. Taken together, the data on CPMPs do not support a plausible role of CPMPs 
in the pathogenesis of these two types of arteriosclerosis. The data provide converging evidence 
that generalized use of antiplatelet drugs in patients with native CAD underlies low CPMPs. 
In conclusion, the selective increase of Annexin V negative CEMPs and the absence of an 
increase of Annexin V positive CECs in transplant recipients with CAV compared to native CAD is 
indicative of increased endothelial cell activation without increased endothelial cell apoptosis. This 
likely reflects the nature and the localization of the eliciting alloantigen in CAV and the fact 
activated T cells in CAV are cytokine-producing CD4+ cells. We also describe for the first time that 
CPMPs are strikingly lower in patients with native CAD most likely as a result of generalized use of 
antiplatelet drugs. 
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3.3 IMPAIRED CHOLESTEROL EFFLUX CAPACITY AND 
VASCULOPROTECTIVE FUNCTION OF HDL IN HEART 
TRANSPLANT RECIPIENTS*
3.3.1 ABSTRACT 
 
 
Background: High-density lipoprotein (HDL) metabolism is significantly altered in heart transplant 
recipients. We hypothesized that HDL function may be impaired in these patients. 
Methods: Fifty-two patients undergoing coronary angiography between 5 and 15 years after heart 
transplantation were recruited in this cross-sectional study. Cholesterol efflux capacity of 
apolipoprotein B-depleted plasma was analysed using a validated assay. The vasculoprotective 
function of HDL was studied by means of an endothelial progenitor cell migration assay. 
Results: HDL cholesterol levels were similar in heart transplant patients compared to healthy 
controls. However, normalized cholesterol efflux and vasculoprotective function were reduced by 
24.1% (p<0.001) and by 27.0% (p<0.01), respectively, in heart transplant recipients compared to 
healthy controls. HDL function was similar in patients with and without cardiac allograft 
vasculopathy (CAV) and was not related to C-reactive protein (CRP) levels. An interaction effect 
(p=0.0584) was observed between etiology of heart failure before transplantation and steroid use 
as factors of HDL cholesterol levels. Lower HDL cholesterol levels occurred in patients with prior 
ischemic cardiomyopathy not taking steroids. However, HDL function was independent of the 
etiology of heart failure before transplantation and steroid use. The percentage of patients with a 
CRP level greater than or equal to 6 mg/l was 3.92-fold (p<0.01) higher in patients with CAV than 
in patients without CAV. 
Conclusions: HDL function is impaired in heart transplant recipients but is unrelated to CAV-
status. The proportion of patients with a CRP level greater than or equal to 6 mg/l is prominently 
higher in CAV-positive patients. 
 
3.3.2 INTRODUCTION 
 
The long-term success of heart transplantation is limited by cardiac allograft vasculopathy (CAV), 
which is characterized by the coexistence of diffuse fibromuscular intimal hyperplasia and focal 
atherosclerosis1, 2. The pathogenesis of CAV predominantly involves alloimmunity but is modified 
by non-immunological factors including metabolic abnormalities. The prevalence and the incidence 
of CAV have been reported to be increased in heart transplant recipients with decreased high 
density lipoprotein (HDL) cholesterol levels3-6. The association between HDL cholesterol and CAV 
                                                 
* This chapter has been published as: Singh, N., Jacobs, F., Rader, D., Vanhaecke, J., Van 
Cleemput, J., De Geest, B. Impaired cholesterol efflux capacity and vasculoprotective function of 
HDL in heart transplant recipients. Journal of Heart and Lung Transplantation 2014; 33 (5), 499-
506. 
 
CHAPTER 3.3 
 
 74 
may reflect causation but might also be due to residual confounding. One such confounding factor 
is insulin resistance, which is considered to play a role in the pathogenesis of CAV. A 
triglyceride/HDL cholesterol ratio of greater than 3 has been recognized as a marker of insulin 
resistance in overweight subjects7 and constituted a risk factor for CAV and major adverse cardiac 
events in heart transplant recipients8, 9. 
Remodelling of HDL in heart transplant recipients is significantly affected by a lower activity of 
cholesterol ester transfer protein, phospholipid transfer protein, and hepatic lipase10, 11. 
Consequently, these patients are characterized by an increased proportion of large HDL particles 
and reduced pre-ß1-HDL in the presence of normal or even elevated HDL cholesterol levels10, 11. 
These alterations may be partially explained by corticosteroid use12 but may also be potentiated by 
statin intake13. The modified HDL metabolism and associated compositional changes of HDL 
particles may lead to an impaired function of these lipoproteins. Reduced HDL function may also 
occur as a result of ongoing inflammation14. 
The current cross-sectional study evaluated the hypothesis that HDL is dysfunctional in heart 
transplant recipients. To assess cholesterol efflux capacity of HDL, we used a validated assay that 
was designed to integrate the efflux pathways thought to be operative in vivo15. Cholesterol efflux 
capacity analyzed by this assay was a stronger predictor of prevalent atherosclerotic burden than 
HDL cholesterol or apolipoprotein (apo) A-I15. Since cumulative endothelial injury induced by both 
alloimmune responses and non-alloimmune insults is thought to be central in the pathogenesis of 
CAV1, 16, we also assessed the vasculoprotective function of HDL by use of an endothelial 
progenitor cell (EPC) migration assay17, 18. Heart transplant recipients were compared with a 
healthy control reference group. Furthermore, we investigated the hypothesis that HDL function 
would be worse in CAV-positive patients than in CAV-negative patients. 
 
3.3.3 METHODS 
3.3.3.1 Study design  
 
Fifty-two clinically stable patients undergoing coronary angiography between 5 and 15 years after 
heart transplantation were recruited in this cross-sectional study. The clinical characteristics of 
CAV-negative and CAV-positive patients have been described in a previous report19. Heart 
transplant patients with prior congenital heart disease and re-transplanted patients were 
excluded.  The study was approved by the Ethics Committee of the University Hospital 
Gasthuisberg and written informed consent was obtained from all participating subjects. The 
reference control group comprised 25 healthy subjects. 
CAV was graded according to the International Society for Heart and Lung Transplantation 
working formulation of a standardized nomenclature for CAV-201020. Patients with no 
detectable angiographic lesions (CAV0) constitute the CAV-negative group, whereas CAV-
positive group consisted of patients with CAV1, CAV2, and CAV3.  
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3.3.3.2 Analysis of cholesterol efflux capacity 
 
Apo B-depleted plasma was obtained after removal of apo B containing lipoproteins with 
polyethylene glycol (molecular weight 8000) (Sigma-Aldrich, Saint Louis, MO, USA) as 
described21. Cholesterol efflux capacity was analyzed essentially as described before by Khera et 
al.22. J774 cells, derived from a murine macrophage cell line, were plated and radiolabeled with 2 
μCi of 3H-cholesterol (Perkin Elmer, Waltham, Massachussetts, USA) per ml and incubated for 16 
hours at 37°C. Next, 0.3 mM 8-(4-chlorophenylthio)-cyclic AMP (Sigma-Aldrich) was added for 6 
hours to up-regulate ABCA1. Subsequently, efflux media containing 2.8% apo B-depleted plasma 
were added to the cells. Different steps were performed in the presence of the acyl–coenzyme 
A:cholesterol acyltransferase inhibitor CP113,818 (2 µg per ml). Each sample was run in duplicate. 
Radioactive cholesterol was quantified by liquid scintillation counting. The quantity of radioactive 
cholesterol incorporated into cellular lipids was calculated by means of extraction with 0.2N 
NaOH/1% sodium dodecyl sulfate for 30 minutes. Percent efflux was calculated as follows: 
[(microcuries of 3H -cholesterol in medium containing 2.8% apo B–depleted plasma − microcuries 
of 3H -cholesterol in plasma-free medium) / (microcuries of 3H -cholesterol in cellular extract of 
wells not exposed to efflux phase)] x 100. Values of percent efflux of individuals were normalized 
to the value of percent efflux of a plasma pool of 14 healthy individuals that was included in each 
plate to correct for interassay variation. 
 
3.3.3.3 Evaluation of the vasculoprotective function of HDL 
 
The vasculoprotective function of HDL was studied by means of an EPC migration assay as 
described17, 18. Male C57BL/6 mice were used as a homogeneous source of EPCs. Apo B-
depleted plasma was filtered through a 50K membrane (Amicon Ultra; Merck Millipore, Billerica, 
MA, USA). HDL retained on top of the filter was added in the lower chamber at 20% of the original 
plasma concentration. EPCs were allowed to migrate for 5 hours at 37 °C. For quantification, cell 
nuclei were stained with 4’,6-diamidine-2-phenylidole dihydrochloride (DAPI) (Vector Laboratories, 
Burlingame, CA, USA) and EPCs migrated into the lower chamber were counted manually in 7 
randomly selected microscopy fields. All experimental conditions were performed in duplicate. 
 
3.3.3.4 Quantification of human apo A-I in plasma by sandwich enzyme-linked 
immunosorbent assay (ELISA) 
 
Human apo A-I levels in plasma were determined by sandwich ELISA23. The sensitivity of this 
assay is 30 µg/ml.  
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3.3.3.5 Statistical analysis 
 
Fisher’s exact test was used to compare categorical data between two groups using Instat 3 
(Graphpad software, San Diego, CA, USA). Continuous variables were summarized by means, 
standard error of the mean, and sample size, and were compared between two groups by an 
unpaired t-test. If indicated, a transformation (natural logarithm) was applied. Continuous 
parameters between 3 groups were compared by analysis of variance followed by Tukey’s multiple 
comparison post-test. Two-way ANOVA test for interaction was performed using Prism4 
(GraphPad Software, San Diego, CA, USA). A p-value of less than 0.05 was considered 
statistically significant. 
  
3.3.4 RESULTS 
 
3.3.4.1 Characteristics of heart transplant recipients included in the cross-sectional study 
 
Clinical characteristics, laboratory parameters, and immunosuppressive and hypolipidemic therapy 
of heart transplant recipients (n=52) are summarized in Table 3.3.1. Patients were also 
categorized according to heart failure etiology before transplantation. Patients with prior ischemic 
cardiomyopathy (n=23) were older and had higher serum creatinine levels than patients with prior 
non-ischemic cardiomyopathy (n=29). Other parameters did not differ between both groups. 
 
3.3.4.2 Comparison of lipoprotein parameters in healthy controls and heart transplant 
recipients 
 
Lipoprotein parameters in healthy controls (n=25) and heart transplant recipients (n=52) are 
shown in Table 3.3.2. Serum cholesterol and low density lipoprotein (LDL) cholesterol levels were 
18.7% (p<0.001) and 27.9% (p<0.0001) lower in heart transplant recipients than in healthy 
controls, reflecting generalized statin use in patients (98.1%). HDL cholesterol levels and the 
proportion of individuals with a triglyceride/HDL cholesterol ratio greater than or equal to 3 were 
not significantly different between both groups. Apo A-I levels were 11.5% (p<0.05) lower in heart 
transplant recipients than in controls. Since the proportion of male subjects was higher in the 
healthy control group, a separate analysis was performed in male subjects. The difference of apo 
A-I levels was 11.7% (p=0.0687) when male healthy controls (n=12) and male transplant 
recipients (n=42) were compared. 
 
 
 
 
IMPAIRED CHOLESTEROL EFFLUX CAPACITY IN HEART TRANSPLANT RECIPIENTS 
 
 77 
3.3.4.3 Comparison of lipoprotein parameters and C-reactive protein levels between CAV-
negative and CAV-positive heart transplant recipients  
 
A comparison of lipoprotein parameters and C-reactive protein (CRP) level between CAV-negative 
and CAV-positive heart transplant recipients is illustrated in Table 3.3.3. LDL cholesterol levels 
were 15.9% (p<0.05) lower in patients with CAV than in patients without CAV, reflecting a policy to 
switch to more potent statins after the diagnosis of CAV. The proportion of patients with a 
triglyceride/HDL cholesterol ratio greater than or equal to 3 was not significantly different between 
CAV-negative and CAV-positive patients. The median CRP level was 2.24-fold (p=0.082) higher in 
patients with CAV than in patients without CAV.  
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Table 3.3.1. Clinical characteristics, laboratory parameters, and immunosuppressive and 
hypolipidemic therapy of all heart transplant recipients and of patients dichotomized 
according to heart failure etiology. 
 
All heart 
transplant 
recipients 
(n=52) 
Prior ischemic 
cardiomyopathy 
(n=23) 
Non-ischemic 
cardiomyopathy 
(n=29) 
P value 
Age at inclusion in the 
study (years) 
61.3 ± 1.9 64.9 ± 1.5 58.4 ± 3.1 0.0489 
Sex (male/female) 80.8%/19.2% 95.7%/4.3% 69.0%/31.0% 0.0300 
Donor age (years) 37.9 ± 1.9 37.4 ± 2.8 38.2 ± 2.6 0.848 
Time after heart 
transplantation (years) 
10.2 ± 0.5 10.4 ± 0.7 10.1 ± 0.7 0.813 
Sex mismatch graft (%) 17.3% 13.0% 20.7% 0.714 
Acute rejection episodes 
(Grade 3A or > 3A) 
11.5% 13.0% 10.3% 1.00 
Current smoker (%) 5.77% 8.70% 3.45% 0.578 
Hypertension (%) 96.2% 95.7% 96.6% 1.00 
Diabetes (%) 28.9% 39.1% 20.7% 0.218 
Body mass index (kg/m2) 26.0 ± 0.4 26.6 ± 0.7 25.5 ± 0.6 0.215 
Platelet count (109/L) 224 ± 10 219 ± 12 227 ± 15 0.672 
Leukocyte count (109/L) 6.84 ± 0.20 6.90 ± 0.31 6.80 ± 0.25 0.789 
Monocyte count (109/L) 0.322 ± 0.030 0.315 ± 0.043 0.328 ± 0.043 0.843 
Lymphocyte count (109/L) 1.27 ± 0.09 1.37 ± 0.15 1.18 ± 0.11 0.294 
Neutrophil count (109/L) 3.50 ± 0.25 3.24 ± 0.32 3.71 ± 0.37 0.343 
Creatinine (mg/dl) 1.48 ± 0.07 1.65 ± 0.11 1.35 ± 0.07 0.0212 
Statins (%) 98.1% 100% 96.6% 1.00 
Cyclosporine (%) 26.9% 30.4% 24.1% 0.755 
Tacrolimus (%) 67.3% 60.9% 72.4% 0.553 
Everolimus (%) 13.5% 17.4% 10.3% 0.686 
Azathioprine (%) 11.5% 21.7% 3.45% 0.0762 
Mycophenolate mofetil 
(%) 
71.2% 73.9% 69.0% 0.765 
Steroid (%) 44.2% 34.8% 51.7% 0.269 
Data of continuous variables represent means ± SEM. P values represent the comparison of 
patients transplanted for ischemic and for non-ischemic cardiomypathy. 
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Table 3.3.2. Comparison of lipoprotein parameters in healthy controls and heart 
transplant recipients. 
 Healthy controls 
(n=25) 
Transplant recipients 
(n=52) 
P value 
Age at inclusion in the study (years) 43.2 ± 2.0 61.3 ± 1.9 <0.0001 
Sex (male/female) 12 (48.0%)/13 (52%) 42 (80.8%)/10 (19.2%) 0.0068 
Cholesterol (mg/dl) 196 ± 8 161 ± 5 0.0002 
Triglycerides (mg/dl) 104 ± 8 118 ± 8 0.192 
HDL cholesterol (mg/dl) 59.5 ± 3.0 54.6 ± 2.3 0.206 
LDL cholesterol (mg/dl) 115 ± 7 83.3 ± 3.4 <0.0001 
Triglyceride/HDL cholesterol ratio 1.91 ± 0.21 2.36 ± 0.18 0.0994 
Triglyceride/HDL cholesterol ratio ≥ 3 4 (16.0%) 13 (25.0%) 0.558 
Apolipoprotein A-I (mg/dl) 137 ± 5 121 ± 4 0.0235 
Data are expressed as means ± SEM for continuous variables. 
 
Table 3.3.3. Comparison of lipoprotein parameters and CRP level between CAV-negative 
and CAV-positive heart transplant recipients. 
 Patients without 
CAV (n=22) 
Patients with  
CAV (n=30) 
P value 
Age at inclusion in the study (years) 56.3 ± 3.2 64.9 ± 2.1 0.0212 
Sex (male/female) 18 (81.8%)/4 (18.2%) 24 (80.0%)/6 (20.0%) 1.00 
Cholesterol (mg/dl) 168 ± 8 156 ± 6 0.211 
Triglycerides (mg/dl) 108 ± 7 125 ± 12 0.244 
HDL cholesterol (mg/dl) 55.0 ± 2.9 54.2 ± 3.4 0.487 
LDL cholesterol (mg/dl) 91.7 ± 5.7 77.1 ± 4.0 0.0436 
Triglyceride/HDL cholesterol ratio 2.08 ± 0.17 2.57 ± 0.28 0.144 
Triglyceride/HDL cholesterol ratio ≥ 3 3 (13.6%) 9 (30.0%) 0.200 
Apolipoprotein A-I (mg/dl) 128 ± 6 117 ± 5 0.176 
CRP (mg/l) 2.99 (1.85-6.65) 6.71 (3.25-12.0) 0.0817 
Data are expressed as means ± SEM for continuous variables or median (IQR). 
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3.3.4.4 Cholesterol efflux capacity and vasculoprotective function of HDL are impaired in 
heart transplant recipients but do not differ between CAV-negative and CAV-
positive patients 
 
Normalized cholesterol efflux was reduced by 24.1% (p<0.001) in heart transplant recipients 
compared to healthy controls (Figure 3.3.1A). This difference was 27.8% (p<0.001) when male 
patients (n=42) were compared with male healthy controls (n=12). No significant difference of 
normalized cholesterol efflux was observed between CAV-negative and CAV-positive patients 
(Figure 3.3.1B). 
 
 
Figure 3.3.1. Individual value bar graph of normalized cholesterol efflux capacity values in healthy 
controls versus heart transplant recipients (panel A) and in CAV-negative versus CAV-positive 
patients (panel B). Data points show the individual values. Means are shown by the horizontal 
lines. 
 
The vasculoprotective function of HDL was evaluated by EPC migration assay in modified Boyden 
chambers. Figure 3.3.2A shows a comparison of reference values in the absence of HDL and the 
number of migrated cells in the presence of HDL from healthy controls and transplant recipients. 
EPC migration was increased by 2.49-fold (p<0.001) and 1.96-fold (p<0.001) by the addition of 
HDL of healthy controls and heart transplant recipients, respectively, at 20% of the plasma 
concentration. EPC migration in the presence of HDL of healthy controls was 27.0% (p<0.01) 
higher than after addition of HDL of heart transplant recipients. When the analysis was restricted 
to male subjects, EPC migration following addition of HDL from healthy individuals was 39.9% 
(p<0.01) higher compared to HDL from heart transplant patients. EPC migration induced by HDL 
of patients with CAV was similar compared to EPC migration induced by HDL of patients without 
CAV (Figure 3.3.2B). The vasculoprotective function of HDL was not significantly correlated with 
cholesterol efflux capacity and HDL function was not related to CRP levels (data not shown). 
Taken together, generalized HDL dysfunction is observed in heart transplant recipients. 
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Figure 3.3.2. Individual value bar graph of vasculoprotective function of HDL evaluated by EPC 
migration assay in modified Boyden chambers. Panel A compares reference values in the 
absence of HDL and the number of migrated cells in the presence of HDL from healthy controls 
and heart transplant recipients. Panel B shows a comparison of reference values in the absence of 
HDL and the number of migrated cells in the presence of HDL from patients without CAV and 
patients with CAV. Data points show the individual values. Means are shown by the horizontal 
lines. 
 
3.3.4.5 HDL cholesterol levels are markedly lower in patients with prior ischemic 
cardiomyopathy than in patients with prior non-ischemic cardiomyopathy but HDL 
function is similar in both groups 
 
Since HDL is an independent risk marker for coronary artery disease, we investigated the 
hypothesis that HDL cholesterol levels and HDL function may differ between patients with prior 
ischemic and prior non-ischemic cardiomyopathy. Table 3.3.4 shows a comparison of lipoprotein 
parameters, HDL function, and CRP level between both groups. HDL cholesterol levels were 
19.7% (p<0.01) lower in patients transplanted for ischemic cardiomyopathy than in patients 
transplanted for non-ischemic cardiomyopathy. This difference was 17.6% (p<0.05) when the 
analysis was restricted to male subjects. The percentage of patients with a triglyceride/HDL 
cholesterol ratio greater than or equal to 3 was 3.80-fold (p<0.05) higher in transplant recipients 
with prior ischemic cardiomyopathy than in patients with prior non-ischemic cardiomyopathy. 
Notwithstanding markedly lower HDL cholesterol levels in patients transplanted for ischemic 
cardiomyopathy, no difference in cholesterol efflux capacity or vasculoprotective function of HDL 
was observed. 
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Table 3.3.4. Comparison of lipoprotein parameters, HDL function, and CRP level 
between patients with ischemic and non-ischemic cardiomyopathy. 
 Ischemic 
Cardiomyopathy 
(n=23) 
Non-ischemic  
cardiomyopathy  
(n=29) 
P value 
Cholesterol (mg/dl) 152 ± 7 168 ± 7 0.352 
Triglycerides (mg/dl) 128 ± 15 109 ± 7 0.102 
HDL cholesterol (mg/dl) 48.0 ± 3.0 59.7 ± 3.1 0.0093 
LDL cholesterol (mg/dl) 78.5 ± 4.3 87.0 ± 5.1 0.220 
Triglyceride/HDL cholesterol ratio 2.87 ± 0.31 1.96 ± 0.16 0.0080 
Triglyceride/HDL cholesterol ratio ≥ 3 9 (39.1%) 3 (10.3%) 0.0210 
Apolipoprotein A-I (mg/dl) 115 ± 5 126 ± 6 0.173 
CRP (mg/l) 9.3 ± 1.7 10.1 ± 3.4 0.435 
CRP ≥ 6 mg/l 11 (47.8%) 8 (27.6%) 0.157 
Normalized cholesterol efflux 0.802 ± 0.051 0.821 ± 0.053 0.793 
Vasculoprotective function 
of HDL (migrated cells/mm2) 
430 ± 26 401 ± 22 0.392 
Data are expressed as means ± SEM for continuous variables. 
 
3.3.4.6 Steroid use is associated with markedly higher HDL cholesterol levels but does 
not affect HDL function 
 
Since the effect of steroids on HDL metabolism may be an important modifier of HDL cholesterol 
levels, a comparison of lipoprotein parameters, HDL function, and CRP levels was performed 
between transplant recipients on steroids (n=23) and those not on steroids (n=29) (Table 3.3.5). 
HDL cholesterol levels were 16.5% (p<0.06) higher in patients on steroids compared to patients 
not on steroids. However, HDL function was similar in both groups. Interestingly, when separate 
analyses were performed in patients with prior ischemic cardiomyopathy and prior non-ischemic 
cardiomyopathy, an interaction effect (p=0.0584) was observed between etiology of heart failure 
before transplantation and steroid use as factors of HDL cholesterol levels. Decreased HDL 
cholesterol levels occurred in patients with prior ischemic cardiomyopathy not taking steroids. 
(Figure 3.3.3). However, this did not result in a different HDL function compared to the other 3 
groups (data not shown). 
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Figure 3.3.3. Individual value bar graph of HDL cholesterol levels in patients with prior ischemic 
cardiomyopathy (circles) and in patients with prior non-ischemic cardiomyopathy (diamonds). 
Open and closed symbols represent patients not taking steroids and patients taking steroids, 
respectively. Data points show the individual values. Means are shown by the horizontal lines. 
 
Table 3.3.5. Comparison of lipoprotein parameters, HDL function and CRP level between 
patients on steroid and patients not on steroid. 
 Patients with 
steroid (n=23) 
Patients without 
steroid (n=29) 
P value 
Age at inclusion in the study (years) 62.5 ± 2.9 60.3 ± 2.6 0.558 
Sex (male/female) 16 (69.6%)/7 (30.4%) 26 (89.7%)/3 (10.3%) 0.0866 
Cholesterol (mg/dl) 167 ± 8 156 ± 6 0.267 
Triglycerides (mg/dl) 129 ± 15 108 ± 6 0.185 
HDL cholesterol (mg/dl) 59.2 ± 3.6 50.8 ± 2.8 0.0552 
LDL cholesterol (mg/dl) 82.7 ± 4.7 83.7 ± 5.0 0.895 
Triglyceride/HDL cholesterol ratio 2.35 ± 0.32 2.37 ± 0.20 0.944 
Triglyceride/HDL cholesterol ratio ≥ 3 4 (17.4%) 9 (31.0%) 0.341 
Apolipoprotein A-I (mg/dl) 128 ± 7 116 ± 5 0.175 
CRP (mg/l) 13.0 ± 4.2 7.2 ± 1.4 0.158 
CRP ≥ 6 mg/l 11(47.8%) 11(37.9%) 0.576 
Normalized cholesterol efflux 0.853± 0.049 0.781 ± 0.053 0.338 
Vasculoprotective function of HDL 
(migrated cells/mm2) 
399 ± 23 426 ± 24 0.424 
Data are expressed as means ± SEM for continuous variables. 
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3.3.4.7 Distinct immunosuppressive regimens do not differentially affect HDL function 
 
The majority of patients in the current study were being treated with the combination 
tacrolimus/mycophenolate mofetil (with or without steroids), which is the current standard 
immunosuppressive regimen in most centers. We compared different parameters in heart 
transplant recipients categorized according to immunosuppression with or without tacrolimus 
(Table 3.3.6) and according to immunosuppression with or without myophenolate mofetil (Table 
3.3.7). HDL cholesterol levels, apo A-I levels, cholesterol efflux capacity of HDL, and 
vasculoprotective function of HDL were similar in patients with or without tacrolimus 
immunosuppression (Table 3.3.6) and in patients with or without myophenolate mofetil 
immunosuppression (Table 3.3.7). The lower triglyceride level in patients on tacrolimus (Table 
3.3.6) is in agreement with data of randomized trials24, 25. 
Furthermore, compared to reference values in healthy controls, the cholesterol efflux capacity of 
HDL (1.071 ± 0.059 versus 0.827 ± 0.047; p=0.0018) and the vasculoprotective function of HDL 
(526 ± 33 versus 404 ± 21; p=0.0018) were impaired in heart transplant recipients taking 
tacrolimus. Similarly, the cholesterol efflux capacity of HDL (1.071 ± 0.059 versus 0.829 ± 0.047; 
p=0.0022) and the vasculoprotective function of HDL (526 ± 33 versus 419 ± 20; p=0.0048) were 
lower in patients treated with myophenolate mofetil compared to healthy controls. Therefore, the 
impairment of cholesterol efflux capacity and of the vasculoprotective function of HDL in heart 
transplant recipients appears to be independent of the specific immunosuppressive regimen. 
However, this does not exclude that immunosuppressive drugs may be directly implicated in 
impaired HDL function. 
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Table 3.3.6. Comparison of lipoprotein parameters, HDL function and CRP level between 
patients on tacrolimus and patients not on tacrolimus. 
 Patients with 
tacrolimus (n=35) 
Patients without 
tacrolimus (n=17) 
P value 
Age at inclusion in the study (years) 59.7 ± 2.4 64.4 ± 3.1 0.249 
Sex (male/female) 25 (71.4%)/10 (28.6%) 17 (100%)/0 (0%) 0.0206 
Cholesterol (mg/dl) 159 ± 6 165 ± 9 0.599 
Triglycerides (mg/dl) 106 ± 6 141 ± 20 0.0333 
HDL cholesterol (mg/dl) 56.5 ± 3.0 50.6 ± 3.0 0.236 
LDL cholesterol (mg/dl) 81.6 ± 4.5 86.6 ± 5.2 0.498 
Triglyceride/HDL cholesterol ratio 2.09 ± 0.17 2.93 ± 0.40 0.0259 
Triglyceride/HDL cholesterol ratio ≥ 3 6 (17.1%) 7 (41.2%) 0.0890 
Apolipoprotein A-I (mg/dl) 124 ± 5 116 ± 7 0.389 
CRP (mg/l) 9.24 ± 2.28 10.8 ± 4.2 0.721 
CRP ≥ 6 mg/l 14 (40.0%) 7 (41.2%) 1.00 
Normalized cholesterol efflux 0.827± 0.047 0.783 ± 0.059 0.571 
Vasculoprotective function of HDL 
(migrated cells/mm2) 
404 ± 21 435 ± 28 0.397 
Data are expressed as means ± SEM for continuous variables. 
 
Table 3.3.7. Comparison of lipoprotein parameters, HDL function and CRP level between 
patients on mycophenolate mofetil and patients not on mycophenolate mofetil. 
 Patients with 
mycophenolate 
mofetil (n=37) 
Patients without 
mycophenolate 
mofetil (n=15) 
P value 
Age at inclusion in the study (years) 59.6 ± 2.2 65.2 ± 3.5 0.182 
Sex (male/female) 30 (81.1%)/7 (18.9%) 12 (80.0%)/3 (20.0%) 1.00 
Cholesterol (mg/dl) 163 ± 6 156 ± 8 0.481 
Triglycerides (mg/dl) 116 ± 10 122 ± 10 0.738 
HDL cholesterol (mg/dl) 55.3 ± 2.9 52.7 ± 3.6 0.613 
LDL cholesterol (mg/dl) 85.0 ± 4.4 79.0 ± 4.9 0.432 
Triglyceride/HDL cholesterol ratio 2.33 ± 0.23 2.45 ± 0.26 0.754 
Triglyceride/HDL cholesterol ratio ≥ 3 9 (24.3%) 4 (26.7%) 1.00 
Apolipoprotein A-I (mg/dl) 122 ± 4 121 ± 10 0.990 
CRP (mg/l) 9.25 ± 2.06 11.0 ± 5.0 0.703 
CRP ≥ 6 mg/l 17 (46.0%) 5 (33.3%) 0.539 
Normalized cholesterol efflux 0.829± 0.047 0.773 ± 0.049 0.497 
Vasculoprotective function of HDL 
(migrated cells/mm2) 
419 ± 20 402 ± 31 0.655 
Data are expressed as means ± SEM for continuous variables. 
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3.3.5 DISCUSSION 
 
The salient findings of the present study are that 1) notwithstanding similar HDL cholesterol levels 
in heart transplant recipients compared to healthy controls, HDL function measured by two highly 
distinct assays is decreased in heart transplant patients; 2) HDL function is not different between 
CAV-negative and CAV-positive patients; 3) the proportion of patients with a CRP level equal to or 
greater than 6 mg/l is prominently higher in CAV-positive patients. 
HDL cholesterol levels were similar in heart transplant recipients compared to healthy controls. 
The healthy controls contained a higher proportion of female subjects and were younger 
compared to heart transplant patients. In prospective studies that are not affected by survival bias, 
HDL cholesterol levels decrease with age in men and women26. Irrespective of potential sources of 
bias in this comparison, we focused on potential determinants of HDL cholesterol levels in these 
patients. Our a priori hypothesis was that HDL cholesterol levels would be influenced by 
corticosteroid use and by heart failure etiology before transplantation. In line of known effects of 
corticosteroids on HDL metabolism and HDL cholesterol levels12, HDL cholesterol levels were 
higher in patients on corticosteroids compared to patients on a steroid-free immunosuppressive 
regimen. On the other hand, HDL cholesterol levels were significantly lower in patients with prior 
ischemic cardiomyopathy than in patients with prior non-ischemic cardiomyopathy. This cannot be 
explained by the worse renal function or by the slightly higher age in patients transplanted for 
ischemic cardiomyopathy. Since low HDL cholesterol is an independent risk marker for coronary 
artery disease27, lower HDL cholesterol concentrations in these patients after heart transplantation 
probably reflect the pretransplant status. Unexpectedly, an interaction was observed between 
etiology of heart failure before transplantation and steroid use as determinants of HDL cholesterol 
levels. Taken together, the absence of a difference of HDL cholesterol levels between heart 
transplant recipients and healthy controls should be interpreted in light of the interaction between 
these two factors.  
Because HDL particles carry more than 80 different proteins and more than 200 lipid species as 
well as several microRNAs28, the structural and functional complexity of HDL cannot be captured 
by a simple biochemical HDL metric such as HDL cholesterol. Therefore, we evaluated two highly 
distinct dimensions of HDL function: the cholesterol efflux capacity and the vasculoprotective 
function of HDL as analyzed by an EPC migration assay. A marked decline of HDL function was 
observed in heart transplant recipients but no difference in HDL function occurred according to 
CAV-status. Furthermore, HDL function was not affected by corticosteroid use and was not 
different in patients with prior ischemic cardiomyopathy compared to prior non-ischemic 
cardiomyopathy. De la Llera-Moya et al.29 have previously demonstrated that the cholesterol efflux 
capacity of apo B-depleted serum is significantly correlated with the concentration of pre-ß1-HDL. 
Serum pre-ß1-HDL depends on the activity of phospholipid transfer protein, hepatic lipase, and 
cholesterol ester transfer protein30, 31. Pre-ß1-HDL is significantly lower in heart transplant 
recipients than in healthy controls11, which is likely related to the lower activities of these three 
enzymes. Lower pre-ß1-HDL may be one factor that underlies the lower cholesterol efflux capacity 
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of apo B-depleted sera of heart transplant recipients. In general, HDL dysfunction may be due to 
post-translational modifications of proteins or to compositional changes of the proteome or the 
lipidome28. Importantly, the correlation between cholesterol efflux capacity and vasculoprotective 
function of HDL was weak, indicating that the attenuation of both dimensions of HDL function in 
heart transplant recipients reflect distinct biochemical alterations of HDL. The impaired stimulation 
of murine EPC migration by HDL from heart transplant recipients is consistent with impaired 
migration of endogenous EPCs in these patients19. 
In two prospective studies, CRP levels and the triglyceride/HDL cholesterol ratio, considered to be 
a marker of insulin resistance, were independent risk markers for CAV and major adverse cardiac 
events8, 9. In the current cross-sectional study, we observed that the proportion of patients with a 
CRP level greater than or equal to 6 mg/l was higher in CAV-positive patients than in CAV-
negative patients. However, the percentage of patients with a triglyceride/HDL cholesterol ratio 
greater than or equal to 3 was not significantly higher in the CAV-positive group. Although this may 
be related to a lack of statistical power, this may also be related to the lower body mass index of 
patients in the current study compared to prior studies14, 15. Furthermore, whether the proposed 
cut-off value of 3 of this parameter is a sensitive and specific marker of insulin resistance has not 
been validated in heart transplant recipients. Considering the likely impact of steroids on HDL 
cholesterol levels and on insulin sensitivity, the interpretation of the triglyceride/HDL cholesterol 
ratio in heart transplant recipients may be cumbersome. 
In conclusion, HDL function measured by two highly distinct assays is decreased in heart 
transplant patients. HDL dysfunction may be related to alterations of HDL metabolism in these 
patients or to undefined compositional alterations that have an overriding negative impact.  
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3.4 ENDOTHELIUM-ENRICHED MICRORNAs PREDICT THE 
PRESENCE OF CARDIAC ALLOGRAFT VASCULOPATHY*
3.4.1 ABSTRACT  
 
 
Background: Cardiac allograft vasculopathy (CAV) is a limiting factor for the long-term survival of 
heart transplant recipients. Clinical decisions and care may be improved by the development of 
prediction models based on circulating biomarkers. The endothelium may play a central 
pathogenetic role in the development of CAV. We evaluated the hypothesis that endothelium-
enriched microRNAs (miRNAs) discriminate between patients with CAV and patients without CAV. 
Methods: Fifty-two patients undergoing coronary angiography between 5 and 15 years after heart 
transplantation were recruited in this cross-sectional study. Circulating levels of endothelium-
enriched miRNAs (miR-21-5p, miR-92a-3p, miR-92a-1-5p, miR-126-3p, miR-126-5p) were 
quantified by real-time RT-PCR. The discriminative ability of logistic regression models was 
evaluated using the concordance statistic (c-statistic).  
Results: Median plasma levels of miR-21-5p, miR-92a-3p, miR-126-3p, and miR-126-5p were 
1.82-fold (p=NS), 1.87-fold (p<0.05), 1.94-fold (p=0.074), and 1.59-fold (p=0.060) higher, in 
patients with CAV than in patients without CAV. Recipient age (c-statistic 0.689 (95% CI 0.537-
0.842)), serum creatinine (c-statistic 0.703 (95% CI 0.552-0.854)), levels of miR-92a-3p (c-statistic 
0.682 (95% CI 0.533-0.831)), and levels of miR-126-5p (c-statistic 0.655 (95% CI 0.502-0.807)) 
predicted CAV-status in univariable models. In multivariable logistic regression models with 
recipient age and creatinine as covariates, miR-126-5p (χ²=4.37; df=1; p=0.037), miR-92a-3p 
(χ²=6.01; df=1; p=0.014), and the combination of miR-126-5p and miR-92a-3p (χ²=8.16; df=2; 
p=0.017) added significant information. The model with age, creatinine, miR-126-5p, and miR-92a-
3p as covariables conferred good discrimination between patients without CAV and patients with 
CAV (c-statistic 0.800 (95% CI 0.674-0.926)). 
Conclusion: Endothelium-enriched miRNAs have predictive ability for CAV beyond clinical 
predictors. 
 
3.4.2 INTRODUCTION 
Cardiac allograft vasculopathy (CAV) is a limiting factor for the long-term survival of heart 
transplant recipients1,2. CAV is characterized by the development of diffuse concentric 
fibromuscular intimal hyperplasia lesions in epicardial and smaller intramyocardial arteries along 
with focal, eccentric atherosclerotic plaques in the larger epicardial arteries3,4. The development of 
these lesions may lead to the progressive narrowing of the lumen5. According to the response to 
injury hypothesis of CAV, these lesions are the result of cumulative endothelial injury induced by 
                                                 
*This chapter has been submitted as: Singh, N., Heggermont, W., Fieuws, S., Vanhaecke, J., Van 
Cleemput, J., De Geest, B. Endothelium-enriched microRNAs predict the presence of cardiac 
allograft vasculopathy. 2015. 
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alloimmune responses as well as non-immunological risk factors such as ischemia-reperfusion 
injury, viral infections, and metabolic disorders3,6.  
Early diagnosis of CAV is essential to implement appropriate prevention and treatment measures. 
Metabolic parameters like triglycerides to HDL cholesterol ratio7,8 and plasma insulin level9 may 
discriminate between CAV-positive and CAV-negative patients. Immunological and inflammatory 
biomarkers of CAV include donor-specific anti-HLA antibodies10, antibodies against 
heterogeneous nuclear ribonucleoprotein K11, C-reactive protein (CRP)8,12-14, vascular cell 
adhesion molecule-115, and circulating C-X-C motif chemokine 12 (CXCL12) levels16. However, 
the discriminative ability and the incremental value of these biomarkers beyond clinical risk factors 
have not been robustly established. Candidate-based approaches using biomarkers of endothelial 
homeostasis may constitute a solid foundation for the development of prediction models of CAV. 
The angiogenesis-related proteins vascular endothelial growth factor (VEGF)-C, VEGF-A and 
platelet factor-4 have been identified as independent biomarkers of CAV17.  In a recent cross-
sectional study18, we demonstrated that a logistic regression model containing apoptotic circulating 
endothelial cells (CECs) and apoptotic circulating endothelial microparticles (CEMPs) as 
independent predictors provided high discrimination between CAV-positive and CAV-negative 
patients (c-statistic 0.812; 95% CI 0.692-0.932). In several logistic regression models including 
clinical and biochemical covariates, the introduction of apoptotic CECs and apoptotic CEMPs 
consistently resulted in added value, indicating that these biomarkers are robust independent 
predictors.  
In line with previous studies demonstrating the ability of biomarkers related to endothelial 
homeostasis to predict CAV, the aim of the current study was to analyze the potential of 
endothelium-enriched microRNAs (miRNAs) as putative biomarkers for the prediction of CAV. 
MiRNAs are small, non-coding, single-stranded RNA sequences that regulate gene expression at 
the post-transcriptional level. Because miRNAs circulate in remarkably stable forms in blood19,20, 
they have a significant potential as biomarkers. Several reports indicate that miRNAs may play a 
role in endothelial homeostasis21,22. In this study, a candidate-based approach using circulating 
levels of endothelium-enriched miRNAs (miR-21-5p, miR-92a-3p, miR-92a-1-5p, miR-126-3p, 
miR-126-5p) to predict CAV was investigated. 
 
3.4.3 METHODS 
3.4.3.1 Study design 
Fifty-two clinically stable patients undergoing coronary angiography between 5 and 15 years after 
heart transplantation were included in this cross-sectional study. In addition, eighty patients with 
clinically stable native coronary artery disease (CAD) were recruited in the study. Stable native 
CAD patients were defined by the presence of at least one stenosis of 50% or more demonstrated 
by diagnostic coronary angiography. CAV was graded according to the International Society for 
Heart and Lung Transplantation working formulation of a standardized nomenclature for CAV-
201023. The clinical characteristics of CAV-negative and CAV-positive patients have been 
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described in a previous report18. Heart transplant patients with prior congenital heart disease and 
re-transplanted patients were excluded. The study was approved by the Ethics Committee of the 
University Hospital Gasthuisberg and written informed consent was obtained from all participating 
subjects. The reference control group included 25 healthy control subjects (12 males and 13 
females) with an average age of 43.2 ± 2.0 years24. 
 
3.4.3.2 Quantification of circulating levels of endothelium-enriched miRNAs (miR-21-5p, 
miR-92a-3p, miR-92a-1-5p, miR-126-3p, miR-126-5p) in plasma samples 
This study was not preceded by a screening phase evaluating a large pool of miRNAs for 
association with CAV-status. The endothelium-enriched miRNAs (miR-21, miR-92a, miR-126) 
investigated in this study were a priori selected based on an analysis of the literature and no other 
miRNAs were quantified. Peripheral blood was drawn by venipuncture using Vacutainer 
collection tubes (BD Diagnostics, Franklin Lakes, NJ, USA). Plasma derived from EDTA 
anticoagulated peripheral blood was centrifuged within one hour after collection at 1900 g for 10 
min followed by a second centrifugation at 1900 g for 20 min to generate platelet-poor plasma 
(PPP) that was used for miRNA quantification by real-time PCR. RNA was isolated from 400µl 
plasma using the Ambion mirVANA RNA extraction kit (AM1560, Applied Biosciences, Austin, 
Texas, USA) according to the instructions of the manufacturer. Subsequently, 300 nanogram of 
RNA was reverse-transcribed to cDNA using the miScript-II RT PCR kit (218061, Qiagen Benelux 
NV, Venlo, The Netherlands) according to the manufacturer’s protocol. Real‐time PCR was 
performed on an ABI-Prism cycler (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) 
using LNATM-based miRNA primers (Exiqon A/S, Vedbaek, Denmark) and SYBR Green (Life 
Technologies, Carlsbad, CA, USA). U6 non-coding small nuclear RNA (snRNA) expression was 
measured as an endogenous control for data normalization. U6 primers were designed by 
Eurogentec (Eurogentec, Seraing, Belgium). MiRNA expression levels were compared using the 
relative threshold cycle (Ct) method (2–∆∆Ct). 
 
3.4.3.3 Statistical analysis 
Clinical and biochemical parameters and endothelial biomarkers were compared using Instat 3 
(Graphpad software, San Diego, CA, USA). Continuous variables were summarized by means, 
standard error of the mean, and sample size, and were compared by Student t-test between CAV-
negative and CAV-positive patients and between CAV-positive patients and stable native CAD 
patients. When data were not normally distributed, data are presented as medians and 
interquartile range (IQR), and were compared by a Mann-Whitney Test. Logistic regression 
analysis was performed by SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA). Since 
the distribution of the concentration of CECs and of CRP is heavily right-skewed, a natural 
logarithm transformation of the data of these two parameters was applied for logistic regression 
analysis. The discriminative ability was quantified using the concordance statistic (C-statistic), 
which is equal to the area under the receiver operating characteristic curve. Evaluation of added 
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value of predictors in multivariable logistic regression models was based on likelihood-ratio tests 
comparing two nested models. A p-value of less than 0.05 was considered statistically significant. 
 
3.4.4 RESULTS 
3.4.4.1 Characteristics of heart transplant recipients without and with CAV and of patients 
with stable native CAD 
The clinical characteristics of heart transplant recipients without CAV (n=22) and with CAV (n=30), 
and of patients with stable native CAD (n=80) are shown in Table 3.4.1. Patients with CAV were 
8.6 years (p<0.05) older than patients without CAV and 4.7 years (p<0.05) younger than patients 
with stable native CAD at the time of inclusion in the study. Patients with stable native CAD had a 
lower prevalence of hypertension (p<0.0001) and a higher body mass index (p<0.05) compared to 
patients with CAV. No significant difference of these two parameters was observed between 
patients without CAV and patients with CAV. Lipoprotein levels were similar among the three 
patient groups except LDL cholesterol, which was 15.9% (p<0.05) lower in patients with CAV than 
in patients without CAV. Creatinine levels were significantly higher in patients with CAV than in 
patients without CAV (p<0.05) as well as in patients with stable native CAD (p<0.0001). There was 
a trend (p=0.082) for higher CRP levels in patients with CAV compared to patients without CAV. 
Median CRP was 4.33-fold (p<0.0001) higher in patients with CAV than in patients with stable 
native CAD. Statin use was generalized in all the three patient groups. 
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Table 3.4.1. Clinical characteristics, laboratory parameters, immunosuppressive and 
hypolipidemic therapy of patients without CAV, patients with CAV and of patients with 
stable native CAD. 
 
Patients without  
CAV 
(n=22) 
Patients with  
CAV  
(n=30) 
Patients with stable 
native CAD 
(n=80) 
Age at inclusion in the 
study (years) 
56.3 ± 3.2 64.9 ± 2.1* 69.6 ± 1.2† 
Sex (male/female) 81.8%/18.2% 80.0%/20.0% 78.8%/21.3% 
Donor age (years) 33.8 ± 2.9 40.8 ± 2.4 N.A. 
Time after heart 
transplantation (years) 
9.35 ± 0.58 10.9 ± 0.8 N.A. 
Age of the transplanted 
heart (years) 
43.2 ± 3.0 51.7 ± 2.3* N.A. 
Sex mismatch graft (%) 13.6% 20.0% N.A. 
Acute rejection episodes 
(Grade 3A or > 3A) 
13.6% 10.0% N.A. 
Current smoker (%) 13.6% 0% 7.5% 
Hypertension (%) 90.9% 100% 47.5%†††† 
Diabetes (%) 18.2% 36.7% 25.0% 
Body mass index (kg/m2) 26.6 ± 0.8 25.5 ± 0.5 27.5 ± 0.6† 
Cholesterol (mg/dl) 168 ± 8 156 ± 6 160 ± 4 
Triglycerides (mg/dl) 108 ± 7 125 ± 12 132 ± 7 
HDL cholesterol (mg/dl) 55.0 ± 2.9 54.2 ± 3.4 50.2 ± 1.8 
LDL cholesterol (mg/dl) 91.6 ± 5.7 77.1 ± 4.0* 83.6 ± 3.0 
Creatinine (mg/dl) 1.32 ± 0.10 1.60 ± 0.08* 1.05 ± 0.03†††† 
CRP (mg/l) 2.99 (1.85-6.65) 6.71 (3.25-12.0) 1.55 (0.60-2.99)†††† 
Statins (%) 95.5% 100% 95.0% 
Cyclosporine (%) 31.8% 23.3% N.A. 
Tacrolimus (%) 63.6% 70.0% N.A. 
Everolimus (%) 4.55% 20.0% N.A. 
Azathioprine (%) 9.10% 13.3% N.A. 
Mycophenolate mofetil (%) 86.4% 60.0% N.A. 
Steroid (%) 18.2% 63.3%** N.A. 
Data of continuous variables represent means ± SEM or median (IQR). 
* : p<0.05, ** : p<0.01, and *** : p<0.001 for patients with CAV versus patients without CAV. 
† : p<0.05, †† : p<0.01, ††† : p<0.001, and †††† : p<0.0001 for patients with stable native CAD 
versus patients with CAV. 
N.A.: not applicable. 
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3.4.4.2 Circulating endothelium-enriched miRNA levels are higher in patients with CAV 
compared to patients without CAV 
All miRNA levels (Figure 3.4.1, Figure 3.4.2) were normalized against U6 snRNA level. As shown 
in Figure 3.4.1A, median plasma miR-21-5p level was 2.34-fold (p<0.05) increased in patients with 
CAV compared to healthy controls whereas no increase was observed in CAV-negative patients. 
Median plasma miR-21-5p level was 1.82-fold (p=NS) higher in CAV-positive patients compared to 
CAV-negative patients (Figure 3.4.1A). Median plasma miR-92a-3p in patients with CAV was 3.08-
fold (p<0.01) and 1.87-fold (p<0.05) higher, respectively, compared to healthy controls and 
patients without CAV (Figure 3.4.1B). As shown in Figure 3.4.1C, median plasma miR-92a-1-5p 
was 2.11-fold increased (p=0.075) in patients with CAV compared to healthy controls but no 
significant difference was observed between CAV-negative and CAV-positive patients. Median 
plasma miR-126-3p in CAV-positive patients was 2.80-fold (p<0.01) and 1.94-fold (p=0.074) 
higher, respectively, compared to healthy controls and CAV-negative patients. Finally, median 
plasma miR-126-5p in patients with CAV was 2.02-fold (p<0.05) and 1.59-fold (p=0.060) 
increased, respectively, compared to healthy controls and patients without CAV. Taken together, 
these results demonstrate that levels of several circulating endothelium-enriched miRNAs are 
increased in patients with CAV compared to patients without CAV. 
 
3.4.4.3 Circulating levels of miR-92a-3p and miR-92a-1-5p differ in patients with CAV and 
in patients with stable native CAD 
Median plasma levels of miR-21-5p, miR-92a-3p, miR-92a-1-5p, miR-126-3p, and miR-126-5p 
were 2.38-fold (p<0.01), 1.98-fold (p<0.01), 3.16-fold (p<0.0001), 3.10-fold (p<0.0001), and 1.90-
fold (p<0.0001) higher, respectively, in patients with stable native CAD (Figure 3.4.2) than in 
healthy controls (Figure 3.4.1). Whereas all of these 5 endothelium-enriched miRNAs were 
elevated in both CAV and native CAD, two distinctions in miRNA levels were observed between 
these two types of arteriosclerosis. Median plasma level of miR-92a-3p was elevated 1.56-fold 
(p=0.051) in CAV-positive patients compared to patients with stable native CAD (Figure 3.4.2B). In 
contrast, median plasma level of miR-92a-1-5p was 1.50-fold (p=0.089) higher in patients with 
native CAD compared to patients with CAV (Figure 3.4.2C).  
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Figure 3.4.1. Individual value bar graph illustrating a comparison of plasma level of miR-21-5p 
(panel A), miR-92a-3p (panel B), miR-92a-1-5p (panel C), miR-126-3p (panel D), and miR-126-5p 
(panel E) in healthy controls (n=25), patients without CAV (n=22), and patients with CAV (n=30). 
All miRNA levels were normalized against U6 snRNAlevel. Data points show the individual values. 
Medians are shown by the horizontal lines. 
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Figure 3.4.2. Individual value bar graph showing a comparison of plasma level of miR-21-5p 
(panel A), miR-92a-3p (panel B), miR-92a-1-5p (panel C), miR-126-3p (panel D) and miR-126-5p 
(panel E) in patients with CAV (n=30) versus patients with stable native CAD (n=80). All miRNA 
levels were normalized against U6 snRNAlevel. Data points show the individual values. Medians 
are shown by the horizontal lines. 
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3.4.4.4 Strong correlation between plasma levels of four miRNAs in heart transplant 
recipients 
Table 3.4.2 shows the Spearman’s rank correlation matrix of endothelium-enriched miRNAs and 
apoptotic CECs and apoptotic CEMPs. With the exception of miR-92a-3p, endothelium-enriched 
miRNAs were strongly correlated (Spearman’s rank correlation coefficient higher than 0.8). 
Plasma levels of miR-21-5p, miR-92a-1-5p, miR-126-3p, and miR-126-5p were weakly correlated 
with apoptotic CECs whereas the level of miR-92a-3p was weakly correlated with apoptotic 
CEMPs. Plasma miRNA levels were not related to clinical parameters (data not shown). 
 
3.4.4.5 Logistic regression models for discrimination between CAV-positive and CAV-
negative transplant recipients  
Table 3.4.3 summarizes the odds ratio per standard deviation increase and the c-statistic values of 
univariable logistic regression models for clinical and biochemical parameters and endothelial 
biomarkers. Plasma levels of miR-126-5p and of miR-92a-3p predicted CAV-status significantly 
better than chance (Table 3.4.4). Since the levels of these two miRNAs were only weakly 
correlated, miR-126-5p and miR-92a-3p were further analyzed in multivariable logistic regression 
models. Discrimination between CAV-negative and CAV-positive transplant recipients based on 
multivariable logistic regression models is shown in Table 3.4.4. Data in relation to the previously 
published model with age, creatinine, apoptotic CECs, and apoptotic CEMPs as predictors18 are 
shown as reference values. The model with age, creatinine, miR-126-5p, and miR-92a-3p as 
covariables conferred good discrimination between patients without CAV and patients with CAV 
(c-statistic 0.800 (95% CI 0.674-0.926)). In a logistic regression model with recipient age and 
creatinine as covariates, miR-126-5p (χ²=4.37; df=1; p=0.037), miR-92a-3p (χ²=6.01; df=1; 
p=0.014), and the combination of miR-126-5p and miR-92a-3p (χ²=8.162; df=2; p=0.017) added 
significant information. In addition, miR-92a-3p (χ²=5.45; df=1; p=0.0195) and not miR-126-5p (chi-
square=2.04; df=1; p=0.15) added value in a model with apoptotic CECs and apoptotic CEMPs as 
predictors. The receiver operating characteristic curve for the logistic regression model with 
apoptotic CECs, apoptotic CEMPs, and miR-92a-3p as predictors is shown in Figure 3.4.3. Taken 
together, these data indicate that endothelium-enriched miRNAs have predictive ability for CAV 
beyond clinical predictors or other endothelial biomarkers. 
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Table 3.4.2. Spearman’s rank correlation matrix of endothelium-enriched miRNAs and apoptotic CECs and apoptotic 
CEMPs. 
 
miR-21-5p miR-92a-3p miR-92a-1-
5p 
miR-126-3p miR-126-5p Apoptotic 
CECs  
Apoptotic 
CEMPs  
miR-21-5p 1.00 0.552**** 0.791**** 0.808**** 0.754**** 0.252 0.176 
miR-92a-3p 0.552**** 1.00 0.288* 0.479*** 0.312* -0.0612 0.276 
miR-92a-1-5p 0.791**** 0.288* 1.00 0.855**** 0.866**** 0.343* 0.0891 
miR-126-3p 0.808**** 0.479*** 0.855**** 1.00 0.863**** 0.341* 0.180 
miR-126-5p 0.754**** 0.312* 0.866**** 0.863**** 1.00 0.351* 0.167 
Apoptotic CECs  0.252 -0.0612 0.343* 0.341* 0.351* 1.00 0.0820 
Apoptotic CEMPs  0.176 0.276 0.0891 0.180 0.167 0.0820 1.00 
CEC: circulating endothelial cell. CEMP: circulating endothelial microparticle. * : p<0.05, ** : p<0.01, *** : p<0.001 and **** 
: p<0.0001. CECs expessed as ln number/µl. CEMPs expressed as number/µl. 
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Table 3.4.3. Odds ratios and c-statistic values of univariable logistic regression models for 
clinical and biochemical parameters and endothelial biomarkers. 
 Odds Ratios P value c-statistic 
Age (years) 1.98 (1.05-3.72) 0.0336 0.689 (0.537-0.842) 
Creatinine (mg/dL) 1.99 (1.02-3.86) 0.0425 0.703 (0.552-0.854) 
CRP (ln mg/l) 1.74 (0.94-3.21) 0.0776 0.643 (0.488-0.799) 
Apoptotic CECs (ln number/µl) 2.32 (1.14-4.71) 0.0196 0.709 (0.567-0.851) 
Apoptotic CEMPs (number/µl) 3.24 (1.17-8.96) 0.0234 0.697 (0.554-0.840) 
miR-21-5p 1.97 (0.95-4.10) 0.0706 0.617 (0.458-0.776) 
miR-92a-3p 4.04 (1.09-14.9) 0.0362 0.682 (0.533-0.831) 
miR-92a-1-5p 1.34 (0.75-2.38) 0.327 0.553 (0.394-0.712) 
miR-126-3p 1.95 (1.00-3.77) 0.0485 0.647 (0.494-0.800) 
miR-126-5p 1.97 (0.91-4.27) 0.0865 0.655 (0.502-0.807) 
CEC: circulating endothelial cell. CEMP: circulating endothelial microparticle. Odds ratios 
are expressed per standard deviation increase. The c-statistic corresponds to the area 
under the ROC curve. The 95% confidence interval is indicated between brackets. 
 
Table 3.4.4. Discrimination between CAV-negative and CAV-positive transplant recipients 
based on receiver operating characteristic analysis of multivariable logistic regression 
models. 
 c-statistic (95% CI) 
Age + creatinine 0.703 (0.552-0.854) 
Apoptotic CECs + apoptotic CEMPs 0.812 (0.692-0.932) 
Age + creatinine + apoptotic CECs + apoptotic CEMPs 0.855 (0.756-0.953) 
miR-126-5p + miR-92a-3p 0.732 (0.586-0.878) 
Age + creatinine + miR-126-5p 0.768 (0.635-0.901) 
Age + creatinine + miR-92a-3p 0.783 (0.649-0.917) 
Age + creatinine + miR-126-5p + miR-92a-3p 0.800 (0.674-0.926) 
Apoptotic CECs + apoptotic CEMPs + miR-126-5p 0.815 (0.699-0.931) 
Apoptotic CECs + apoptotic CEMPs + miR-92a-3p 0.847 (0.740-0.954) 
Apoptotic CECs + apoptotic CEMPs + miR-126-5p + miR-92a-3p 0.852 (0.746-0.957) 
The c-statistic corresponds to the area under the ROC curve. CEC: circulating endothelial 
cell. CEMP: circulating endothelial microparticle. CI: confidence interval. 
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Figure 3.4.3. Receiver-operating characteristic curve for the logistic regression model with 
apoptotic CECs, apoptotic CEMPs, and miR-92a-3p as predictors. The area under this curve is 
equal to the C-statistic. 
 
3.4.5 DISCUSSION 
The salient findings of the present study are that 1) several endothelium-enriched miRNAs are 
increased in the plasma of CAV-positive patients compared to CAV-negative patients; 2) whereas 
all investigated endothelium-enriched miRNAs are increased both in heart transplant recipients 
with CAV and in patients with native CAD compared to healthy controls, two of five endothelium-
enriched miRNAs are distinct in these two types of arteriosclerosis; 3) plasma levels of miR-126-
5p and of miR-92a-3p predict CAV-status in univariable models; and 4) these endothelium-
enriched miRNAs have predictive ability for CAV beyond clinical predictors or other endothelial 
biomarkers. 
Biomarkers that capture key processes in the pathogenesis of CAV, e.g. biomarkers related to 
endothelial homeostasis18, may be the cornerstone for adequate prediction models. The five 
miRNAs analysed in this study (miR-21-5p, miR-92a-3p, miR-92a-1-5p, miR-126-3p, and miR-
126-5p) are endothelium-enriched miRNAs and have been shown to play a role in endothelial 
homeostasis21,25. MiR-21 negatively modulates angiogenesis by targeting RhoB expression26. The 
precursor miRNA miR-21 gives rise to two mature miRNAs: miR-21-3p and miR-21-5p. MiR-21-5p 
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is an important regulator of neointimal hyperplasia development after balloon injury27,28. MiR-92a 
represses angiogenesis29, 30 and promotes endothelial activation31. MiR-92a-3p and miR-92a-1-5p 
are two distinct mature miRs produced from the same precursor miRNA pre-miR-92a-1. Finally, 
miR-126 is one of the most abundant miRNAs in endothelial cells and is involved in the regulation 
of vascular integrity and angiogenesis32. MiR-126-3p and miR-126-5p are two distinct mature 
miRNAs arising from the same precursor pre-miR-126. MiR-126-3p has been shown to confer 
anti-inflammatory effects by inhibiting expression of vascular cell adhesion molecule 1 and 
sprouty-related protein 133,34. MiR-126-5p enhances endothelial proliferation via inhibition of the 
Notch1 inhibitor delta-like 1 homolog (Dlk1)35. Thus, the two miR-126 strands play a role in 
endothelial repair mechanisms in response to continuous endothelial inflammation and apoptosis 
resulting in endothelial damage. Taken together, the specific functions of the different miRNAs 
investigated in the current study may be biologically relevant for the development of CAV. 
However, the focus of the current study is the development of prediction models of prevalent 
disease. Therefore, a potential causal role of any of these miRNAs is not under consideration in 
this report. Interestingly, all investigated miRNAs were increased both in heart transplants 
recipients with CAV and in patients with native CAD compared to healthy controls. Nevertheless, 
whereas plasma levels of miR-92a-3p were elevated in CAV-positive patients compared to 
patients with stable native CAD, the opposite pattern was observed for miR-92a-1-5p. This 
distinction in endothelial biology between these two types of arteriosclerosis is also reflected by 
our previous report demonstrating that markers of endothelial injury are distinct in patients with 
stable native CAD and with CAV36. 
Whereas miRNAs have been investigated as non-invasive biomarkers for heart transplant 
rejection37,38, this is the first report to demonstrate the discriminative ability of miRNAs in clinical 
prediction models of prevalent CAV. A strong correlation of plasma levels of 4 of the 5 investigated 
endothelium-enriched miRNAs was observed in heart transplant recipients. Therefore, 
consideration of all miRNAs for multivariable modeling was not meaningful and could have led to 
multicollinearity problems. Moreover, given the number of patients included in the current study, 
the number of predictors in multivariable models had to be limited. The model with age, creatinine, 
miR-126-5p, and miR-92a-3p as covariables conferred good discrimination between patients 
without CAV and patients with CAV and both endothelium-enriched miRNAs had predictive ability 
for CAV beyond clinical predictors. However, this model does not provide better discrimination 
compared to the previously published model with age, creatinine, apoptotic CECs, and apoptotic 
CEMPs as predictors18. Nevertheless, plasma level of miR-92a-3p added value in a model with 
apoptotic CECs and apoptotic CEMPs as predictors, which may provide a foundation for a model 
with improved discrimination. Since the number of subjects in the current study was limited to 22 
CAV-negative patients and 30 CAV-positive patients, we cannot test whether plasma level of miR-
92a-3p adds information beyond the previously established model with age, creatinine, apoptotic 
CECs, and apoptotic CEMPs as predictors. Inclusion of too many predictors leads to overfitting of 
the data and C-indices are overestimated38. Specifically, models with more than 3 predictors 
should be interpreted with extreme caution considering the sample size. A larger study is required 
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to analyse the discriminative ability of a model including clinical predictors, apoptotic CECs, and 
apoptotic CEMPs, and miR-92a-3p. 
There is a biological rational why an endothelium-enriched miRNA has predictive ability for CAV 
beyond clinical predictors or beyond apoptotic CEMPs and apoptotic CECs. Although miRNAs can 
be released by apoptosis or necrosis, miRNAs can also enter the circulation in exosomes. 
Exosomes are built by inward budding of the limiting cell membrane of the multivesicular body, a 
late endosomal compartment40. The fusion of the multivesicular body with the plasma membrane 
leads to the active secretion of exosomes into the blood circulation. Since this active secretion 
process is fundamentally distinct from apoptosis or necrosis, it is not surprising that no strong 
correlation is observed between different miRNAs and apoptotic CECs and apoptotic CEMPs. This 
lack of a strong correlation is a necessary condition to contribute additional information to the 
prediction of CAV. Taken together, plasma levels of endothelium-enriched miRNAs reflect at least 
in part a different dimension of endothelial biology. 
In conclusion, the current study enforces the paradigm that endothelial biomarkers constitute a 
solid foundation for clinical prediction models of CAV. Plasma levels of miR-126-5p and miR-92a-
3p added value in models with age and creatinine as predictors. The observation that miR-92a-3p 
has predictive ability beyond apoptotic CEMPs and apoptotic CECs may lead to the development 
of models with further improved performance. 
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In order to avoid repetition, the objective of this chapter is not to present a comprehensive 
discussion of the scientific work of this PhD thesis. The aim of this chapter is to present selected 
topics that have been not discussed in detail in the different papers comprised in this doctoral 
thesis.  
 
4.1 C-REACTIVE PROTEIN AS A PREDICTOR OF PREVALENT 
CAV 
As described in chapter 3.3, the median C-reactive protein (CRP) level was 2.24-fold (p=0.082) 
higher in patients with cardiac allograft vasculopathy (CAV) than in patients without CAV. In a 
univariable logistic regression model, the odds ratio per standard deviation increase of CRP (ln 
transformed) was 1.74 (95% CI 0.94-3.21) (p=0.078) and the c-statistic corresponding to this 
model was 0.643 (95% CI 0.488-0.799). Although statistical significance was not reached, this 
likely reflects a lack of statistical power. Furthermore, lack of statistical significance in a univariable 
model does not preclude added value in a multivariable model. 
The odds ratios of a multivariable logistic regression model containing apoptotic circulating 
endothelial cells (CECs) (ln transformed), apoptotic circulating endothelial microparticles (CEMPs), 
and CRP (ln transformed) as predictors are shown in Table 4.1. CRP (χ²=9.08; df=1; p=0.0026) 
added value in the model with apoptotic CECs and apoptotic CEMPs as predictors. The receiver 
operating characteristic curve of the logistic regression model with apoptotic CECs, apoptotic 
CEMPs, and CRP as predictors is shown in Figure 4.1. The c-statistic corresponding to this model 
is 0.870 (95% CI 0.774-0.966). 
 
4.2 OVERFITTING AND OVEROPTIMISM 
A key threat to the usefulness of the predictions is overfitting. This refers to the phenomenon that 
the sample is well described by the model, but that the derived predictions are not valid for new 
subjects. Overfitting originates from applying a statistical model with too many degrees of freedom 
(i.e. too many predictors). Degrees of freedom are used (1) in the mere estimation of the 
coefficients in a regression model (‘parameter uncertainty’) and (2) in the search of the optimal 
model structure (‘model uncertainty’). This overfitting will lead to overoptimism with regard to the 
discriminative ability of the model. In a future validation study, a pre-specified model approach can 
be used instead of a model building approach. In a pre-specified model approach, models with a 
selected set of a priori defined predictors are evaluated. The models that will be considered are 
the three following: 
1. age, creatinine, apoptotic CECs, and apoptotic CEMPs; 
2. age, creatinine, apoptotic CECs, and apoptotic CEMPs, CRP; 
3. age, creatinine, apoptotic CECs, and apoptotic CEMPs, miR-92a-3p. 
Considering that there are 5 predictors in two of these models, a validation study should ideally 
contain at least 50 CAV negative patients and 50 CAV positive patients1.  
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Table 4.1. Logistic regression model containing apoptotic CECs, apoptotic CEMPs and 
CRP, as predictors for prediction of CAV. 
 
 OR P value 
Apoptotic CECs (ln number/µl) 4.52 (1.52-13.5) 0.0067 
Apoptotic CEMPs (number/µl) 6.45 (1.42-29.2) 0.0156 
CRP (ln mg/l) 3.73 (1.39-10.0) 0.0090 
 
The 95% confidence interval is indicated between brackets. Odds ratios (OR) are 
expressed per standard deviation increase. 
 
 
 
 
 
Figure 4.1. Receiver-operating characteristic curve for the logistic regression model with apoptotic 
CECs, apoptotic CEMPs, and CRP as predictors. The area under this curve is equal to the c-
statistic. 
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4.3 ENDPOINTS IN HEART TRANSPLANTATION RESEARCH 
AND THE DEVELOPMENT OF PROGNOSTIC PREDICTION 
MODELS FOR INCIDENT DISEASE 
CAV was graded according to the International Society for Heart and Lung Transplantation 
working formulation of a standardized nomenclature for CAV-20102. Therefore, the performance of 
diagnostic prediction models was evaluated in terms of their ability to predict the prevalence of 
CAV defined according to angiographic criteria. An angiographic definition of CAV is likely 
pathophysiologically relevant. However, since intimal proliferation in CAV is circumferential and 
since the disease process is diffuse extending into intramyocardial vessels, it is not entirely clear 
how strong the correlation is between angiographic abnormalities and the functional deterioration 
of the coronary circulation. Furthermore, one should also keep in mind that an angiographic 
imaging end-point is a surrogate end-point that is used to predict major adverse cardiac events, 
late graft failure, and mortality. 
The development of a prognostic prediction model for incident CAV or hard clinical end-points was 
not considered.  The development of such a model requires a long-term prospective study that is 
beyond the scope of this doctoral thesis. Intravascular ultrasound (IVUS) is a particularly sensitive 
method to detect early CAV and may demonstrate significant intimal thickening in the presence of 
a normal coronary angiogram3. The validity of the increase in maximal intimal thickness quantified 
by IVUS as a surrogate imaging end-point for subsequent angiographic disease and for hard 
clinical end-points has been demonstrated3-5. IVUS could be used to define surrogate imaging 
end-point in a prospective study. The short-term objective of such a prospective study would be 
the development of a prediction model (multiple linear regression) for the change (increase) of the 
maximal intimal thickness (MIT) between 3 weeks and 1 year after transplant. Clearly, the long-
term objective would be the prediction of hard clinical end-points. It is clear that such a prospective 
study would be complicated by a very substantial cost and also by a likely long recruitment phase 
of patients. 
 
4.4 HDL FUNCTION AND THE HDL HYPOTHESIS  
Recently, Rohatgi et al.6 demonstrated that cholesterol efflux capacity, measured at the time of 
inclusion in 2924 participants in the Dallas Heart Study free from cardiovascular disease at 
baseline, was inversely associated with the incidence of atherosclerotic cardiovascular disease. 
This end-point was defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary 
revascularization or death from cardiovascular causes. The assay applied by Rohatgi et al.6 is 
similar to the assay used by Khera et al.7, which is identical to the procedure applied in chapter 3.3 
of this doctoral thesis. These assays primarily evaluate cholesterol efflux mediated by ATP-binding 
cassette transporter A1 (ABCA1). There is one essential difference between the assay of Rohatgi 
et al.6 and the assay of Khera et al.7. The fluorescence-labeled reagent boron dipyrromethene 
difluoride (BODIPY) cholesterol was used by Rohatgi et al.6, whereas efflux was measured using 
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radiolabeled cholesterol in the study of Khera et al.7. Surprisingly, the cholesterol efflux capacity 
evaluated with BODIPY cholesterol was only moderately correlated with measurements performed 
with radiolabeled cholesterol (correlation coefficient for normalized cholesterol efflux 0.54). This 
illustrates that these assays are very delicate to execute and that they are not characterized by the 
same level of reproducibility compared to assays in clinical biology. There is also a complete lack 
of standardization in this area. Li et al.8 observed that heightened cholesterol efflux to apoB-
depleted serum was paradoxically associated with increased prospective risk for myocardial 
infarction, stroke, and death. This raises the question why these results contrast with those of 
Rohatgi et al.6. First of all, due to the specific design of the study of Li et al.8, their findings may 
reflect index event bias. Secondly, Li et al.8 used THP-1 cells and 2% apo B-depleted serum, 
whereas in the studies of  Khera et al. 7 and  Rohatgi et al.6 murine J774 cells and 2.8% apo B-
depleted serum were used. There are additional distinctions between these assays and all these 
differences support the thesis that results of these assays have a different significance. Taken 
together, whereas this field is confounded by a lack of standardization, the recent results of 
Rohatgi et al.6 support the general validity of the cholesterol efflux assay used in chapter 3.3. 
However, since this assay was not used in the setting of native atherosclerosis in chapter 3.3 and 
since this cholesterol efflux capacity is likely highly influenced by the background therapy of these 
patients, any conclusion beyond the mere fact that cholesterol efflux capacity is substantially 
reduced in heart transplant recipients is speculative. 
According to this HDL hypothesis, raising HDL cholesterol is expected to lead to a decrease of 
coronary heart disease risk9. In a more lipoprotein-centric than cholesterol-centric view, this 
hypothesis states that raising ‘HDL’ will lead to a decrease of coronary events. The most important 
argument against the HDL hypothesis is the recent Mendelian randomization Voight et al.10. They 
constructed a genetic score for HDL cholesterol combining the HDL-cholesterol-raising alleles at 
each of 14 single nucleotide polymorphisms. Each of these single nucleotide polymorphisms had 
statistical evidence at genome wide levels of significance for association with plasma HDL 
cholesterol and no evidence for association with triglycerides or LDL cholesterol. In Mendelian 
randomization analysis, a 1 standard deviation rise in HDL cholesterol due to the genetic score 
was not associated with risk of myocardial infarction. This is in sharp contrast with lowered risk of 
myocardial infarction associated with a 1 standard deviation rise in HDL cholesterol in 
observational epidemiology. Therefore, the possibility that the epidemiological relationship 
between HDL cholesterol and coronary artery disease reflects residual confounding merits serious 
consideration. 
In the modified HDL hypothesis, it is postulated that enhanced HDL function will result in a 
reduction of coronary events9. However, the shift from a biochemical surrogate end-point to a 
functional surrogate end-point does not solve by itself the uncertain value of surrogate end-points9. 
Taken together, the HDL hypothesis remains unproven. The study of HDL function in heart 
transplant recipients is unlikely to yield substantial additional information beyond the results 
described in chapter 3.3. 
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Cardiac allograft vasculopathy (CAV) is a limiting factor for the long-term survival of heart 
transplant recipients1,2. CAV is characterized by the development of diffuse concentric 
fibromuscular intimal hyperplasia in epicardial and smaller intramyocardial arteries along with 
focal, eccentric atherosclerotic plaques in the larger epicardial arteries3,4. The development of 
these lesions may lead to the progressive narrowing of the lumen5. According to the response to 
injury hypothesis of CAV, these lesions are the result of cumulative endothelial injury induced by 
alloimmune responses as well as non-immunological risk factors such as ischemia-reperfusion 
injury, viral infections, and metabolic disorders3,6.  
Early diagnosis of CAV is essential to implement appropriate prevention and treatment measures. 
Clinical prediction models of CAV are currently not available and may be useful for non-invasive 
diagnostic and prognostic purposes. The general aim of this doctoral thesis is to develop 
diagnostic prediction models for prevalent CAV. The specific central hypothesis of this doctoral 
thesis is that biomarkers of endothelial homeostasis discriminate between CAV-negative and 
CAV-positive heart transplant recipients.  
Endothelial homeostasis reflects the balance between endothelial injury and endothelial repair. In 
chapter 3.1, we investigated whether biomarkers related to endothelial injury and endothelial 
repair discriminate between CAV-negative and CAV-positive heart transplant recipients. Fifty-two 
patients undergoing coronary angiography between 5 and 15 years after heart transplantation 
were recruited in this study. Flow cytometry was applied to quantify endothelial progenitor cells 
(EPCs), circulating endothelial cells (CECs), and circulating endothelial microparticles (CEMPs). 
Cell culture was used for quantification of circulating EPC number and hematopoietic progenitor 
cell (HPC) number and for analysis of EPC function. EPC number and EPC function did not differ 
between CAV-negative and CAV-positive patients. In univariable models, age, creatinine, steroid 
dose, granulocyte colony-forming units, apoptotic CECs, and apoptotic CEMPs discriminated 
between CAV-positive and CAV-negative patients. The logistic regression model containing 
apoptotic CECs and apoptotic CEMPs as independent predictors provided high discrimination 
between CAV-positive and CAV-negative patients (c-statistic 0.812; 95% CI 0.692-0.932). In a 
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logistic regression model with age and creatinine as covariates, apoptotic CECs (p=0.0112) and 
apoptotic CEMPs (p=0.0141) were independent predictors (c-statistic 0.855; 95% CI 0.756-0.953). 
These two biomarkers remained independent predictors when steroid dose was introduced in the 
model. Taken together, the high discriminative ability of apoptotic CECs and apoptotic CEMPs is a 
solid foundation for the development of clinical prediction models of CAV. 
In chapter 3.2, patients with stable native coronary artery disease (CAD) were compared with 
heart transplant recipients with CAV. After all, CAV is a particular type of arteriosclerosis with 
many similarities but also significant differences compared to native CAD. Atherosclerosis in 
patients with stable native CAD is characterized by the presence of atheromata that contain a lipid 
core filled with extracellular cholesterol and cellular debris and are covered by a fibrous cap. In 
contrast, fibromuscular intimal hyperplasia is the most prominent lesion type of CAV and mainly 
consists of smooth muscle cells and extracellular matrix7. Endothelial injury is assumed to play a 
key role in the initiation and progression of both native CAD and CAV2,8. In the response-to-injury 
hypothesis of atherosclerosis of Ross and Glomset, endothelial injury was originally defined as 
endothelial denudation resulting from focal desquamation of endothelium9,10. Later versions of the 
response-to-injury hypothesis emphasized endothelial dysfunction rather than denudation8,11. 
Cellular biomarkers of endothelial injury (CEMPs and CECs) may discriminate between 
endothelial activation and irreversible endothelial damage. The hypothesis that endothelial injury 
and circulating platelet microparticles (CPMPs) are distinct in both types of arteriosclerosis was 
investigated.  
The geometric mean of the concentration of CECs (CD45- CD31bright VEGFR-2+) was 2.90-fold 
(p<0.001) and 2.34-fold (p<0.05) higher in patients with stable native CAD (n=80) and with CAV 
(n=30), respectively, compared to healthy controls (n=25). No significant difference in total, 
Annexin V negative, and Annexin V positive (apoptotic) CECs was observed between patients with 
native CAD and with CAV. The concentration of Annexin V negative CEMPs (CD144+ CD42a-) 
was 59.2% (p<0.01) higher in transplant recipients with CAV than in native CAD patients but no 
difference in Annexin V positive CEMPs was observed. The median value of total CD61+ CPMPs 
in native CAD patients was 69.4% (p<0.001) and 71.6% (p<0.001) lower compared to healthy 
controls and transplant recipients with CAV, respectively. These differences were even more 
pronounced when CD42a+CD31+ CPMPs were quantified. In conclusion, the selective increase of 
Annexin V negative CEMPs and the absence of a difference in Annexin V positive CECs strongly 
suggest increased endothelial activation but not endothelial apoptosis in CAV-positive patients 
compared to stable CAD patients. Use of antiplatelet drugs likely underlies the strikingly lower 
levels of CPMPs in patients with native CAD. 
In chapter 3.3, the relation between high density lipoproteins (HDL) and CAV was investigated. 
The prevalence and the incidence of CAV have been reported to be increased in heart transplant 
recipients with decreased high density lipoprotein (HDL) cholesterol levels12-15. The association 
between HDL cholesterol and CAV may reflect causation but might also be due to residual 
confounding. One such confounding factor is insulin resistance, which is considered to play a role 
in the pathogenesis of CAV. A triglyceride/HDL cholesterol ratio of greater than 3 has been 
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recognized as a marker of insulin resistance in overweight subjects16 and constituted a risk factor 
for CAV and major adverse cardiac events in heart transplant recipients17,18. 
Remodelling of HDL in heart transplant recipients is significantly affected by a lower activity of 
cholesterol ester transfer protein, phospholipid transfer protein, and hepatic lipase19,20. 
Consequently, these patients are characterized by an increased proportion of large HDL particles 
and reduced pre-ß1-HDL in the presence of normal or even elevated HDL cholesterol levels19,20. 
These alterations may be partially explained by corticosteroid use21 but may also be potentiated by 
statin intake22. The modified HDL metabolism and associated compositional changes of HDL 
particles may lead to an impaired function of these lipoproteins. Reduced HDL function may also 
occur as a result of ongoing inflammation23. 
We hypothesized that HDL function may be impaired in these patients and may discriminate 
between CAV-positive and CAV-negative patients. Cholesterol efflux capacity of apolipoprotein 
B-depleted plasma was analysed using a validated assay24. The vasculoprotective function of 
HDL was studied by means of an EPC migration assay. HDL cholesterol levels were similar in 
heart transplant patients compared to healthy controls. However, normalized cholesterol efflux and 
vasculoprotective function were reduced by 24.1% (p<0.001) and by 27.0% (p<0.01), respectively, 
in heart transplant recipients compared to healthy controls. HDL function was similar in patients 
with and without cardiac allograft vasculopathy (CAV) and was not related to C-reactive protein 
(CRP) levels. An interaction effect (p=0.0584) was observed between etiology of heart failure 
before transplantation and steroid use as factors of HDL cholesterol levels. Lower HDL cholesterol 
levels occurred in patients with prior ischemic cardiomyopathy not taking steroids. However, HDL 
function was independent of the etiology of heart failure before transplantation and steroid use. 
The median C-reactive protein (CRP) level was 2.24-fold (p=0.082) higher in patients with CAV 
than in patients without CAV. In conclusion, HDL function is impaired in heart transplant recipients 
but is unrelated to CAV-status. The proportion of patients with a CRP level greater than or equal to 
6 mg/l is prominently higher in CAV-positive patients.  
In chapter 3.4, the potential of endothelium-enriched microRNAs (miRNAs) as putative biomarkers 
for the prediction of CAV was investigated. MiRNAs are small, non-coding, single-stranded RNA 
sequences that regulate gene expression at the post-transcriptional level. Because miRNAs 
circulate in remarkably stable forms in blood25,26, they have a significant potential as biomarkers. 
Several reports indicate that miRNAs may play a role in endothelial homeostasis27,28. In this study, 
a candidate-based approach using circulating levels of endothelium-enriched miRNAs (miR-21-5p, 
miR-92a-3p, miR-92a-1-5p, miR-126-3p, miR-126-5p) to predict CAV was evaluated. Circulating 
levels of endothelium-enriched miRNAs (miR-21-5p, miR-92a-3p, miR-92a-1-5p, miR-126-3p, 
miR-126-5p) were quantified by real-time RT-PCR. The discriminative ability of logistic regression 
models was quantified using the concordance statistic (c-statistic). Plasma levels of miR-21-5p, 
miR-92a-3p, miR-126-3p, and miR-126-5p were 1.86-fold (p=NS), 1.91-fold (p<0.05), 1.74-fold 
(p=0.074), and 1.73-fold (p=0.060) higher, in patients with CAV than in patients without CAV. 
Recipient age (c-statistic 0.689 (95% CI 0.537-0.842)), serum creatinine (c-statistic 0.703 (95% CI 
0.552-0.854)), levels of miR-92a-3p (c-statistic 0.682 (95% CI 0.533-0.831)), and levels of miR-
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126-5p (c-statistic 0.655 (95% CI 0.502-0.807)) predicted CAV-status in univariable models. In a 
multivariable logistic regression model with recipient age and creatinine as covariates, miR-126-5p 
(chi-square=4.374; df=1; p=0.0365), miR-92a-3p (chi-square=6.007; df=1; p=0.0143), and the 
combination of miR-126-5p and miR-92a-3p (chi square=8.162; df=2; p=0.0169) added significant 
information. The model with age, creatinine, miR-126-5p and miR-92a-3p as covariables conferred 
good discrimination between patients without CAV and patients with CAV (c-statistic 0.800 (95% 
CI 0.674-0.926)). In addition, miR-92a-3p (chi-square=5.454; df=1; p=0.0195) and not miR-126-5p 
(chi-square=2.037; df=1; p=0.1535) added value in a model with apoptotic CECs and apoptotic 
CEMPs as predictors (c-statistic0.847 (95% CI 0.740-0.954)). In conclusion, endothelium-enriched 
miRNAs have predictive ability for CAV beyond clinical predictors. 
The central hypothesis at the start of this doctoral thesis was that biomarkers of endothelial 
homeostasis discriminate between CAV-negative and CAV-positive heart transplant recipients. 
The validity of this hypothesis has been convincingly demonstrated. The refinement and validation 
of these models in a larger follow-up study may lead to a clinically useful model that can be 
applied for monitoring heart transplant recipients. 
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